var title_f32_29_33232="Luikart forceps";
var content_f32_29_33232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Luikart modification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Luikart blade is solid with partial fenestration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aron Schuftan, MD. Copyright &copy; Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33232=[""].join("\n");
var outline_f32_29_33232=null;
var title_f32_29_33233="Interdigital erythrasma";
var content_f32_29_33233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interdigital erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scale and maceration were present in this web space of the foot of a patient with interdigital erythrasma. The three lateral web spaces of both feet were involved. The potassium hydroxide preparation was negative; the Wood's lamp examination showed bright coral red fluorescence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolff K, Goldsmith LA, Katz S, et al. Fitzpatrick's Dermatology in General Medicine, 7th ed, McGraw-Hill Professional 2008. Copyright &copy; 2008 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33233=[""].join("\n");
var outline_f32_29_33233=null;
var title_f32_29_33234="Visceral surface spleen";
var content_f32_29_33234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Visceral surface spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33234=[""].join("\n");
var outline_f32_29_33234=null;
var title_f32_29_33235="Petechiae in subacute bacterial endocarditis";
var content_f32_29_33235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Petechiae in subacute bacterial endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Petechiae are present on the toe in this patient with subacute bacterial endocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33235=[""].join("\n");
var outline_f32_29_33235=null;
var title_f32_29_33236="Summary of public health actions based on blood lead levels";
var content_f32_29_33236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 637px\">",
"   <div class=\"ttl\">",
"    Summary of public health actions based on maternal and infant blood lead levels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 617px; height: 794px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BLL: blood lead level; dept: department; ped: pediatric; m: month.",
"     <br>",
"      * Confirm and referrals.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ettinger AS, Gurthrie Wengrovitz A, (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at",
"     <a href=\"file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" target=\"_blank\">",
"      file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33236=[""].join("\n");
var outline_f32_29_33236=null;
var title_f32_29_33237="Rotavirus vaccine: Pediatric drug information";
var content_f32_29_33237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rotavirus vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42789?source=see_link\">",
"    see \"Rotavirus vaccine: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2553110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rotarix&reg;;",
"     </li>",
"     <li>",
"      RotaTeq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7710124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rotarix&reg;;",
"     </li>",
"     <li>",
"      RotaTeq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2687131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Live Virus",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2687140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42789?source=see_link\">",
"      see \"Rotavirus vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In the event a dose is regurgitated, spit out, or infant vomits, the AAP does not recommend readministration of the dose; subsequent doses should be administered on routine schedule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants 6-24 weeks of age (Rotarix&reg;): Oral: 1 mL per dose; a 2-dose series at 2 and 4 months of age. Initial dose should be administered from 6 weeks through 14 weeks 6 days of age; the first and second dose should be separated by &ge;4 weeks. The 2-dose series should be completed by 24 weeks of age; maximum age for last dose: 8 months 0 days of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants 6-32 weeks (RotaTeq&reg;): Oral: 2 mL per dose; a 3-dose series at 2, 4, and 6 months of age. Initial dose should be administered from 6 weeks through 12 weeks; subsequent doses administered at 4- to 10-week intervals. Routine administration of the first dose at &gt;12 weeks of age is not recommended (insufficient data). Administer all doses by 32 weeks of age. Infants who have had rotavirus gastroenteritis before getting the full course of vaccine should still initiate or complete the 3-dose schedule; initial infection provides only partial immunity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ACIP recommendations:",
"     </b>",
"     The first dose can be given at 6-14 weeks of age. The series should not be started in infants &ge;15 weeks. The final dose in the series should be administered by 8 months 0 days of age. The minimum interval between doses is 4 weeks. A total of three doses (administered at 2, 4, and 6 months of age) is recommended; however, if Rotarix&reg; is used at ages 2 and 4 months, a dose at 6 months is not indicated. For infants inadvertently administered rotavirus vaccine at &ge;15 weeks of age, the vaccine series may be completed according to schedule and prior to 8 months and 0 days of age. The ACIP recommendations for vaccination recommend completing the vaccine series with the same product whenever possible. If continuing with same product will cause vaccination to be deferred, or if product used previously is unknown, vaccination should be completed with the product available. If RotaTeq&reg; was used in any previous doses, or if the specific product used was unknown, a total of three doses should be given.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2554565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for suspension, oral [preservative free; human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rotarix&reg;: G1P[8] &ge;10",
"     <sup>",
"      6",
"     </sup>",
"     CCID",
"     <sub>",
"      50",
"     </sub>",
"     per 1 mL [contains sorbitol, sucrose; supplied with diluent which may contain natural rubber/natural latex in packaging]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [preservative free; bovine and human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RotaTeq&reg;: G1 &ge;2.2 x 10",
"     <sup>",
"      6",
"     </sup>",
"     infectious units, G2 &ge;2.8 x 10",
"     <sup>",
"      6",
"     </sup>",
"     infectious units, G3 &ge;2.2 x 10",
"     <sup>",
"      6",
"     </sup>",
"     infectious units, G4 &ge;2 x 10",
"     <sup>",
"      6",
"     </sup>",
"     infectious units, and P1A [8] &ge;2.3 x 10",
"     <sup>",
"      6",
"     </sup>",
"     infectious units per 2 mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2553112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2687281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral use only;",
"     <b>",
"      not for injection",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rotarix&reg;: Connect transfer adapter onto vial and push downwards until transfer adapter is in place. Shake oral applicator containing liquid diluent (suspension will be a turbid liquid). Connect oral applicator to transfer adapter and transfer entire contents of oral applicator into the lyophilized vaccine. With transfer adapter in place, shake vigorously. Withdraw entire mixture back into oral applicator. Infant should be in reclining position. Using oral applicator, administer contents into infant&rsquo;s inner cheek. If most of dose is spit out or regurgitated, may administer a replacement dose at the same visit. Dispose of applicator and vaccine vial in biologic waste container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     RotaTeq&reg;: Clear fluid from the dispensing tip by holding dosing tube vertically and tapping cap; puncture dispensing tip by screwing cap clockwise; remove cap by turning counterclockwise; gently squeeze liquid dose into infant&rsquo;s mouth toward the inner cheek until dosing tube is empty. If an incomplete dose is given (eg, infant spits or regurgitates dose), do not administer replacement dose. The infant can continue to receive any remaining doses of the series at the designated time interval. Do not mix or dilute vaccine with any other vaccine or solution.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2687137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rotarix&reg;: Prior to reconstitution, store powder under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); diluent may be stored at room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light; discard if frozen. Following reconstitution, may be refrigerated or stored at room temperature for up to 24 hours. Discard if frozen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     RotaTeq&reg;: Store and transport under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Administer as soon as possible once removed from refrigerator. Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2687132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Routine immunization to prevent rotavirus gastroenteritis caused by serotypes G1, G2, G3, and G4 (RotaTeq&reg;) or serotypes G1, G3, G4, and G9 (Rotarix&reg;) (Rotarix&reg;: FDA approved in ages 6-24 weeks; RotaTeq&reg;: FDA approved in ages 6-32 weeks)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2553123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967  or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fever &gt;38.1&deg;C, fussiness, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, flatulence, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchospasm, nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, gastroenteritis with severe diarrhea and prolonged vaccine viral shedding in infants with SCID, hematochezia, idiopathic thrombocytopenic purpura, intussusception, Kawasaki disease, seizure, transmission of vaccine virus from recipient to nonvaccinated contacts, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2687133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rotavirus vaccine or any component; infants with severe combined immunodeficiency disease (SCID); infants with history of intussusception. Rotarix&reg; is contraindicated in patients with a history of uncorrected congenital GI malformations (including Meckel&rsquo;s diverticulum) that may predispose them to intussusception.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2983211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in infants with a history of gastrointestinal disorders (eg, active acute gastrointestinal disorders, chronic diarrhea, failure to thrive, history of congenital abdominal disorders, abdominal surgery, and intussusception). Use with caution in immunocompromised infants (including blood dyscrasias, leukemia, lymphoma, malignant neoplasms affecting bone marrow or lymphatic system), infants on immunosuppressants (including high-dose corticosteroids; may be administered with topical corticosteroids or inhaled steroids), or infants with primary and acquired immunodeficiencies (including HIV/AIDS, cellular immune deficiencies, hypogammaglobulinemic and dysgammaglobulinemic states); safety and efficacy have not been established. The ACIP recommendations support vaccination of HIV-exposed or infected infants, since the diagnosis of infection may not be made prior to the first dose of the vaccine and also because strains of rotavirus vaccine are considerably attenuated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rotavirus vaccine may be administered at any time before, concurrent with, or after administration of any blood product, including antibody-containing products. Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever due to vaccines has been shown to decrease the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2687134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Rotavirus vaccine should not be administered to infants with acute, moderate-to-severe gastroenteritis until the condition improves. Rotavirus vaccine administration may be delayed in patients with febrile illness except when the physician decides that withholding the vaccine entails a greater risk. Patients with mild low-grade fever (&lt;38.1&deg;C), mild gastroenteritis, or mild upper respiratory infection may receive vaccine. Information is not available for use of rotavirus vaccine in postexposure prophylaxis. Live virus vaccines may be transmitted to nonvaccinated contacts; use with caution in the presence of immunocompromised family members. The ACIP recommends vaccination of infants living in households with persons who are immunocompromised.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Postmarketing cases of intussusception associated with rotavirus vaccine administration have been reported. Preliminary postmarketing data has found an increased risk of intussusception following the first dose of Rotarix&reg; vaccine in a study conducted in Mexico. Based on an interim analysis, the relative risk of intussusception within 31 days of first vaccination is 1.8 (99% CI: 1-3.1); most cases occurred within the first 7 days. The oral applicator of Rotarix&reg; contains latex. The RotaTeq&reg; dosing tube is latex-free.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2554552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5371979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3274446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Not indicated for use in women of reproductive age. Infants living in households with pregnant women may be vaccinated  (CDC, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2687138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Live viral vaccine that replicates in the small intestine and induces active immunity.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2983212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Infants living in households with pregnant women may be vaccinated. Inform healthcare provider if there has been a previous reaction to rotavirus vaccine. Advise parents to contact the child's physician immediately if stomach pain, vomiting, diarrhea, blood in stool, or change in bowel movements occur after vaccine administration. Immunocompromised individuals should avoid coming in contact with immunized infants' stool (eg, diaper changes).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2983214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Diphtheria and tetanus antigens in DTaP, HIB, IPV, hepatitis B vaccine, and pneumococcal conjugate vaccine may be given concurrently with rotavirus vaccine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In the United States, rotavirus outbreaks occur from late fall to early spring. In the Southwest, the peak rotavirus season is November through December; the peak epidemic travels across the United States from west to east terminating in April through May in the Northeast.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Committee on Infectious Diseases; American Academy of Pediatrics, \"Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 123(5):1412-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/19332437/pubmed\" id=\"19332437\" target=\"_blank\">",
"        19332437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortese MM, Parashar UD, and Centers for Disease Control and Prevention (CDC), \"Prevention of Rotavirus Gastroenteritis Among Infants and Children: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-2):1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/19194371/pubmed\" id=\"19194371\" target=\"_blank\">",
"        19194371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vesikari T, Matson DO, Dennehy P, et al, \"Safety and Efficacy of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(1):23-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/29/33237/abstract-text/16394299/pubmed\" id=\"16394299\" target=\"_blank\">",
"        16394299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13075 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33237=[""].join("\n");
var outline_f32_29_33237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2553110\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710124\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687131\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687140\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2554565\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2553112\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687281\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687137\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687132\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2553123\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687133\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983211\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687134\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300016\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2554552\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5371979\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3274446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2687138\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983212\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983214\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13075\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13075|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42789?source=related_link\">",
"      Rotavirus vaccine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_29_33238="Acrochodae - axilla";
var content_f32_29_33238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acrochordae (skin tags) in the axilla",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple pedunculated papules are present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33238=[""].join("\n");
var outline_f32_29_33238=null;
var title_f32_29_33239="Pharmacotherapy for posttraumatic stress disorder";
var content_f32_29_33239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for posttraumatic stress disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33239/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33239/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33239/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33239/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/29/33239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5614677\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttraumatic stress disorder (PTSD) is a syndrome that occurs in some persons following exposure to potentially life-threatening traumatic events. PTSD is characterized by the ongoing presence of four symptom clusters: frequent re-experiencing of the trauma (eg, as intrusive thoughts, nightmares, or flashbacks), emotional numbing, avoidance behaviors, and persistent hyperarousal. PTSD is associated with considerable social, occupational, and interpersonal dysfunction. PTSD has a lifetime prevalence estimated at 7 percent in the United States (US) general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/1\">",
"     1",
"    </a>",
"    ], and is especially common among veterans of war.",
"   </p>",
"   <p>",
"    Effective treatments for PTSD include medications and psychotherapies. However, a substantial proportion of patients have symptoms resistant to treatment. It is often necessary to switch or combine treatments to achieve a satisfactory therapeutic response.",
"   </p>",
"   <p>",
"    The pharmacological treatment of PTSD is addressed in this topic. The epidemiology, pathophysiology, clinical manifestations, and diagnosis of PTSD are discussed separately, as is psychotherapy for PTSD. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of acute stress disorder are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7080?source=see_link\">",
"     \"Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24197?source=see_link\">",
"     \"Treatment of acute stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614684\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should optimally be initiated shortly after diagnosis. The diagnosis of PTSD is made after persistence of symptoms for at least four weeks following the trauma, but most patients present for treatment many months, or sometimes years, later. In theory, early treatment of PTSD may prevent chronicity, but this not been shown empirically, particularly for pharmacotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic goals of pharmacologic therapy are to decrease intrusive thoughts and images, phobic avoidance, pathological hyperarousal, hypervigilance, irritability and anger, and depression. Drug therapies have generally been most effective in decreasing hyperarousal and mood (irritability, anger, depression) symptoms, and somewhat less effective for the symptoms of re-experiencing, emotional numbing, and behavioral avoidance, but individual differences in response generally outweigh treatment-specific differences. There is a great deal of variation in response to pharmacologic treatment, with few robust individual predictors of response available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Some ancillary symptoms of PTSD, such as sleep disturbance, can be particularly difficult to treat, and are among the symptoms that result in the use of polypharmacy that is so common in the treatment of PTSD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614705\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective serotonin reuptake inhibitors (SSRIs) are first-line medications for the treatment of PTSD. In a meta-analysis of seven randomized trials, patients treated with SSRIs were more likely to experience improvement in symptoms (on the Clinician Administered PTSD Scale or CAPS) and functioning than the group receiving placebo (RR 1.59, 95% CI 1.39 to 1.82) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/7\">",
"     7",
"    </a>",
"    ]. An Institute of Medicine panel on the treatment of PTSD observed that these studies were not consistently positive and varied in quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689775\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs are typically started at the low end of their therapeutic range and titrated up gradually until response is achieved. Usual starting doses, low starting doses, and therapeutic dose ranges for commonly used SSRIs are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef55682 \" href=\"mobipreview.htm?17/4/17484\">",
"     table 1",
"    </a>",
"    ). Although there is not clear evidence of a dose-response relationship for SSRIs in PTSD, it is common practice to push the dose to the very high end of the therapeutic range (to the extent that this is tolerated by the patient) before concluding that a therapeutic trial has failed. Duration of a therapeutic trial of an SSRI should be a minimum of six to eight weeks before concluding that the medication has failed.",
"   </p>",
"   <p>",
"    As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    can be started at 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally. If minimal or no clinical response is seen after three to four weeks, increased doses in 10 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    increments can be tried, up to 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Side effects of SSRIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link&amp;anchor=H399779851#H399779851\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18954665\">",
"    <span class=\"h2\">",
"     Serotonin-norepinephrine reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are fewer studies assessing the efficacy of serotonin-norepinephrine reuptake inhibitors (SNRIs) than SSRIs in PTSD, two randomized trials found",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    extended-release (ER) to be more effective in reducing PTSD symptoms than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As an example, 329 adults with PTSD were randomly assigned to receive venlafaxine ER or placebo for 24 weeks. Patients receiving venlafaxine ER were more likely to experience remission of PTSD symptoms compared to patients receiving placebo (50.9 versus 37.5 percent) (",
"    <a class=\"graphic graphic_table graphicRef55682 \" href=\"mobipreview.htm?17/4/17484\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614719\">",
"    <span class=\"h2\">",
"     Other antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence of the effectiveness of tricyclic antidepressants (TCAs), monoamine oxidase inhibitor (MAOIs), or atypical antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ) for PTSD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614726\">",
"    <span class=\"h2\">",
"     Atypical antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall evidence from clinical trials does not support the use of atypical antipsychotics to augment SSRIs or SNRIs in the treatment of PTSD in military veterans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There are fewer, and only smaller, trials in the non-military population, which have shown mixed findings.",
"   </p>",
"   <p>",
"    Based on the absence of other medications that effectively treat patients with persistent PTSD symptoms following",
"    <span class=\"nowrap\">",
"     SSRI/SNRI",
"    </span>",
"    treatment, the limited trials available on atypical antipsychotics in this population, and our clinical experience that some patients appear to benefit from these agents, we suggest adjunctive use of an atypical antipsychotic for PTSD symptoms resistant to",
"    <span class=\"nowrap\">",
"     SSRIs/SNRIs.",
"    </span>",
"   </p>",
"   <p>",
"    In the largest trial to date, 247 US military veterans who responded inadequately to two or more trials with an SSRI or SNRI were randomly assigned to adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (up to 4 mg once daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients continued to receive other medication and psychosocial interventions for PTSD. After six months, no meaningful difference was seen in overall CAPS score (the primary outcome) compared to placebo, or in symptoms of anxiety, depression, or quality of life. Risperidone led to small, statistically significant mean reductions of uncertain clinical significance in reexperiencing and hyperarousal symptoms. Participants receiving risperidone were more likely to experience weight gain, fatigue, somnolence and hypersalivation compared to patients receiving placebo.",
"   </p>",
"   <p>",
"    Earlier, small trials (involving a total of 134 military veterans) had found adjunctive treatment of PTSD with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    to reduce PTSD symptoms compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings from the relatively large",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    trial cannot be generalized beyond that study&rsquo;s focus on PTSD in an overwhelmingly male (96.6 percent) sample of military veterans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/11\">",
"     11",
"    </a>",
"    ]. There is much less data on the efficacy of the medication in civilians with PTSD, the majority of whom are female, and have experienced more varied types of trauma.",
"   </p>",
"   <p>",
"    Two small trials of adjunctive atypical antipsychotics for PTSD in civilian samples have shown mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An eight-week trial of 21 female patients found treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      augmenting current antidepressant or anxiolytic treatment led to a greater reduction of PTSD symptoms compared to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An eight-week trial of 25 SSRI-resistant patients, mostly female, found no difference between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      and placebo in augmentation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      in the reduction of PTSD symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two small trials have found atypical antipsychotics as monotherapy to decrease PTSD symptoms in civilian samples.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An eight-week trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      monotherapy to placebo in 28 female and male adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients treated with olanzapine experienced greater improvement in PTSD symptoms than patients receiving placebo. Six of 14 patients in the olanzapine group experienced weight gain ranging from 13 to 22 pounds.",
"     </li>",
"     <li>",
"      A ten-week trial of 20 female patients found treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      monotherapy led to a greater reduction of PTSD symptoms compared to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689758\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an example, start",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    at 0.5mg orally, increase after five to seven days if the response is inadequate up to 4",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    If no clinical benefit is seen after two to three weeks of treatment at the maximal tolerated dose, gradually discontinue the medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18954751\">",
"    <span class=\"h2\">",
"     Alpha-adrenergic receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In small randomized trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    has been shown to decrease nightmares and improve sleep in patients with PTSD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. As an example, 12 patients with chronic PTSD, frequent nightmares, and sleep disturbance participated in a randomized crossover trial comparing prazosin to placebo. Patients experienced a greater average sleep time when treated with prazosin compared to placebo (374 versus 280 minutes nightly), and fewer nightmares [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"     Prazosin",
"    </a>",
"    is typically started at 1 mg at bedtime and is gradually increased to 3 to 10 mg as tolerated, using caution to avoid orthostatic hypotension. Sudden discontinuation of prazosin must be avoided, as this can result in rebound hypertension; patients should be cautioned accordingly. Some experience with atypical antipsychotics and prazosin for PTSD suggests that prazosin may be preferred on the basis of its efficacy and tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/20\">",
"     20",
"    </a>",
"    ]. Larger controlled trials of prazosin for PTSD are currently underway. Prazosin is often used adjunctively with SSRIs, though it may be considered as monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18954806\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines have been rarely studied in PTSD, yet they are frequently used to treat symptoms of anxiety and hyperarousal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Given the high prevalence of comorbid substance abuse in patients with PTSD, benzodiazepines should be avoided in patients with a history of substance use, and all patients should be monitored for signs of abuse of the prescribed drug. Benzodiazepines can be useful to treat acute, severe symptoms of hyperarousal during an emergent situation, eg, in an emergency department. However, there is no evidence to support continued use after the acute situation has subsided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18954833\">",
"    <span class=\"h2\">",
"     Mood stabilizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsant medications with mood-stabilizing properties in other psychiatric disorders have been studied for a potential effect on impulsive behavior, hyperarousal, and flashbacks in patients with PTSD, but findings have been mostly negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/3\">",
"     3",
"    </a>",
"    ]. Few adequately powered, randomized trials have been conducted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12-week trial of 232 patients with PTSD found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"       tiagabine",
"      </a>",
"      did not differ from placebo in reducing PTSD symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 12-week trial of 38 patients with non-combat-related PTSD found no difference between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      and placebo on the total score on the Clinician Administered PTSD Scale [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/22\">",
"       22",
"      </a>",
"      ]. A 7-week study of 40 inpatients with PTSD found no difference between topiramate and placebo added to ongoing treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two negative trials compared divalproex to placebo, one with 85 US military veterans with PTSD and the other with 29 civilian patients with PTSD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13508127\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If effective, medication should be continued for at least six months to a year to prevent relapse or recurrence. A clinical trial randomly assigned 96 patients with PTSD who had completed 12 weeks of acute treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    to either 28 weeks of maintenance treatment with sertraline or to placebo. Patients who continued sertraline were less likely to relapse than patients receiving placebo (5 versus 26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614755\">",
"    <span class=\"h1\">",
"     COMPARING PHARMACOTHERAPY AND PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no placebo-controlled, randomized trials comparing SSRIs to psychotherapy for PTSD. Patients with PTSD were included in an early intervention trial comparing CBT and an SSRI to prevent development of chronic PTSD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/27\">",
"     27",
"    </a>",
"    ], but results of the study did not distinguish between patients who had experienced PTSD symptoms for more than 30 days and those who did not. (See",
"    <a class=\"local\" href=\"#H5614776\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614762\">",
"    <span class=\"h1\">",
"     COMBINING PHARMACOTHERAPY AND PSYCHOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1464647\">",
"    <span class=\"h2\">",
"     SSRI antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on our clinical experience, we suggest combined treatment with an antidepressant (an SSRI or SNRI) and CBT that includes exposure for patients who do not respond adequately to either modality individually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/28\">",
"     28",
"    </a>",
"    ]. If no response is seen following an adequate trial with the initial modality, substitution with the second modality is a reasonable approach.",
"   </p>",
"   <p>",
"    Limited clinical research has not found the combination of an",
"    <span class=\"nowrap\">",
"     SSRI/SNRI",
"    </span>",
"    and CBT to lead to greater sustained improvement than either modality alone. A systematic review identified four trials with a total of 122 patients comparing combined",
"    <span class=\"nowrap\">",
"     CBT/SSRI",
"    </span>",
"    for PTSD to CBT alone (2 trials) and to an SSRI alone (2 trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/28\">",
"     28",
"    </a>",
"    ]. Three of the four trials enrolled patients who had not responded to an SSRI, while the fourth trial studied patients independent of their prior treatment status. Results of the trials did not find combined treatment to result in more improvement than monotherapy. Examples of the trials follow. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5032?source=see_link\">",
"     \"Psychotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 88 patients with PTSD were initially treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      for 10 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/29\">",
"       29",
"      </a>",
"      ]. Those who did not achieve a full response to the medication alone were randomly assigned to continue sertraline alone or sertraline augmented with prolonged exposure for an additional five weeks. No difference in PTSD symptom reduction was seen between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a randomized trial, 78 patients with PTSD were initially treated with eight sessions of prolonged exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients experiencing a partial response were randomly assigned to continued prolonged exposure with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    CR or placebo. No difference was seen between the two groups. A more recent trial randomly assigned 37 adults with PTSD to either prolonged exposure in combination with paroxetine or prolonged exposure in combination with placebo for 10 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/31\">",
"     31",
"    </a>",
"    ]. Combined treatment led to greater improvement in PTSD symptoms compared to prolonged exposure alone. No difference between groups was seen in a subset of patients who continued randomized treatment for an additional 12 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614769\">",
"    <span class=\"h2\">",
"     D-cycloserine",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-cycloserine, an NMDA (N-methyl-D-aspartic acid) partial agonist, has shown some promise for augmentation of exposure therapy for anxiety disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/32\">",
"     32",
"    </a>",
"    ]. The drug facilitates extinction of conditioned fear in animal models. It has shown preliminary evidence of decreasing time to a clinical response to exposure therapy for phobias, social anxiety, panic, and obsessive-compulsive disorder. Clinical trials of D-cycloserine in conjunction with exposure therapy for PTSD are underway. At present, there is no evidence to recommend the use of D-cycloserine in the treatment of PTSD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614776\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence supporting the use of pharmacologic interventions in the aftermath of traumatic events to prevent PTSD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24197?source=see_link&amp;anchor=H1238727#H1238727\">",
"     \"Treatment of acute stress disorder\", section on 'Other medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial that used an equipoise-stratified design had one stratum that included 46 individuals who met PTSD criteria an average of a month following exposure to a traumatic event, and accepted randomization to five months of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33239/abstract/27\">",
"     27",
"    </a>",
"    ]. In this small, underpowered stratum, escitalopram was not superior to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/45/8914?source=see_link\">",
"       \"Patient information: Post-traumatic stress disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5614797\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment of PTSD with a trauma-focused cognitive-behavioral therapy (CBT), medication (a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)), or a combination of both modalities (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5032?source=see_link&amp;anchor=H1118664160#H1118664160\">",
"       \"Psychotherapy for posttraumatic stress disorder\", section on 'Cognitive and behavioral therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest first-line treatment of PTSD with a trauma-focused CBT over medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An SSRI or SNRI can be used for first-line treatment in patients who prefer medication to psychotherapy, or when CBT is not available (See",
"      <a class=\"local\" href=\"#H5614755\">",
"       'Comparing pharmacotherapy and psychotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5032?source=see_link&amp;anchor=H1118664160#H1118664160\">",
"       \"Psychotherapy for posttraumatic stress disorder\", section on 'Cognitive and behavioral therapies'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5614705\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18954665\">",
"       'Serotonin-norepinephrine reuptake inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      can be started at 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally and increased up to 60",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5614705\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If effective, we recommend continuing the medication for at least six months to a year to prevent relapse or recurrence (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based on the absence of other medications that effectively treat patients with persistent PTSD symptoms following",
"      <span class=\"nowrap\">",
"       SSRI/SNRI",
"      </span>",
"      treatment, the limited trials available on atypical antipsychotics in this population, and our clinical experience that some patients appear to benefit from these agents, we suggest adjunctive use of an atypical antipsychotic for PTSD symptoms resistant to",
"      <span class=\"nowrap\">",
"       SSRIs/SNRIs",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5614726\">",
"       'Atypical antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As an example, start",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      at 0.5mg orally, increase after five to seven days if the response is inadequate up to 4",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      If no clinical benefit is seen after two to three weeks of treatment at the maximal tolerated dose, gradually discontinue the medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest trauma-focused CBT as an adjunctive treatment in patients with PTSD who have only responded partially to an SSRI or SNRI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Trauma-focused CBT can replace the",
"      <span class=\"nowrap\">",
"       SSRI/SNRI",
"      </span>",
"      in patients who have not responded to an adequate trial of the medication. (See",
"      <a class=\"local\" href=\"#H5614762\">",
"       'Combining pharmacotherapy and psychotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5032?source=see_link\">",
"       \"Psychotherapy for posttraumatic stress disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      for patients with PTSD who experience sleep disruption or nightmares (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This medication can be used alone or as an adjunct to an SSRI or SNRI. (See",
"      <a class=\"local\" href=\"#H18954751\">",
"       'Alpha-adrenergic receptor blockers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/1\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/2\">",
"      Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 2004; 161:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/3\">",
"      Ravindran LN, Stein MB. Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res 2009; 1293:24.",
"     </a>",
"    </li>",
"    <li>",
"     Ravindran LN, Stein MB. Anxiety Disorders: Somatic Treatment. In: Kaplan and Sadock Comprehensive Textbook of Psychiatry, 9th ed, Sadock BJ, Sadock VA, Ruiz P.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2009. p.1906.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/5\">",
"      Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry 2008; 69:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/6\">",
"      Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. Psychiatr Serv 2008; 59:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/7\">",
"      Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006; :CD002795.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Treatment of Posttraumatic Stress Disorder (Institute of Medicine). Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence, The National Academies Press, Washington, DC 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/9\">",
"      Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006; 63:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/10\">",
"      Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006; 26:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/11\">",
"      Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 2011; 306:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/12\">",
"      Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/13\">",
"      Reich DB, Winternitz S, Hennen J, et al. A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 2004; 65:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/14\">",
"      Padala PR, Madison J, Monnahan M, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006; 21:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/15\">",
"      Rothbaum BO, Killeen TK, Davidson JR, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008; 69:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/16\">",
"      Carey P, Suliman S, Ganesan K, et al. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 2012; 27:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/17\">",
"      Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/18\">",
"      Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007; 61:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/19\">",
"      Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003; 160:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/20\">",
"      Byers MG, Allison KM, Wendel CS, Lee JK. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol 2010; 30:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/21\">",
"      Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007; 27:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/22\">",
"      Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/23\">",
"      Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007; 27:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/24\">",
"      Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008; 28:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/25\">",
"      Hamner MB, Faldowski RA, Robert S, et al. A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatry 2009; 21:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/26\">",
"      Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001; 158:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/27\">",
"      Shalev AY, Ankri Y, Israeli-Shalev Y, et al. Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach And Prevention study. Arch Gen Psychiatry 2012; 69:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/28\">",
"      Hetrick SE, Purcell R, Garner B, Parslow R. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2010; :CD007316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/29\">",
"      Rothbaum BO, Cahill SP, Foa EB, et al. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 2006; 19:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/30\">",
"      Simon NM, Connor KM, Lang AJ, et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry 2008; 69:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/31\">",
"      Schneier FR, Neria Y, Pavlicova M, et al. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry 2012; 169:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33239/abstract/32\">",
"      Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63:1118.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 501 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-125.69.132.100-CD8B9207C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33239=[""].join("\n");
var outline_f32_29_33239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5614797\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5614677\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5614684\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5614705\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H689775\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18954665\">",
"      Serotonin-norepinephrine reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5614719\">",
"      Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5614726\">",
"      Atypical antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H689758\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18954751\">",
"      Alpha-adrenergic receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18954806\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18954833\">",
"      Mood stabilizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13508127\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5614755\">",
"      COMPARING PHARMACOTHERAPY AND PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5614762\">",
"      COMBINING PHARMACOTHERAPY AND PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1464647\">",
"      SSRI antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5614769\">",
"      D-cycloserine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5614776\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5614797\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/4/17484\" title=\"table 1\">",
"      SSRI-SNRI dosage PTSD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7080?source=related_link\">",
"      Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/45/8914?source=related_link\">",
"      Patient information: Post-traumatic stress disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/40/24197?source=related_link\">",
"      Treatment of acute stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_29_33240="The gifted child: Educational interventions and primary care management";
var content_f32_29_33240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The gifted child: Educational interventions and primary care management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33240/contributors\">",
"     L. Erik von Hahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33240/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33240/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/29/33240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H184755606\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gifted individuals have exceptional abilities in a particular domain or domains (eg, mathematics, music, athletics). In addition, they typically have high degrees of self-motivation, curiosity, perseverance, and enjoyment in developing and expressing their talents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss educational interventions for and the primary care management of gifted children. The characteristics and identification of giftedness are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link\">",
"     \"The gifted child: Characteristics and identification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466903174\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universally accepted definition for giftedness, which can manifest in a variety of ways. Other terms that are used to describe giftedness include &ldquo;outstanding talent&rdquo;, &ldquo;gifted and talented&rdquo;, and &ldquo;high-ability&rdquo;. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H370340910#H370340910\">",
"     \"The gifted child: Characteristics and identification\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Department of Education (DOE) definition for giftedness is the most widely accepted by researchers and practitioners in the field of giftedness (",
"    <a class=\"graphic graphic_table graphicRef83643 \" href=\"mobipreview.htm?31/13/31963\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/2\">",
"     2",
"    </a>",
"    ]. The DOE definition is similar to that provided by the National Association for Gifted Children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States, most state boards of education provide definitions for",
"    <span class=\"nowrap\">",
"     gifted/giftedness,",
"    </span>",
"    but the definitions may differ from the US DOE definition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/4\">",
"     4",
"    </a>",
"    ]. The definitions used by individual states are available from the",
"    <a class=\"external\" href=\"file://www.nagc.org/GiftedByState.aspx\">",
"     National Association for Gifted Children",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753906\">",
"    <span class=\"h1\">",
"     SCHOOL-HOUSE GIFTEDNESS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184758616\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of intellectual or school-house giftedness, like any form of giftedness, is a long-term endeavor, fostered by early identification, supportive and encouraging parents, and teachers and mentors who place high expectations on the student [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/5\">",
"     5",
"    </a>",
"    ]. Gifted students need to be challenged to maintain interest and high achievement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6\">",
"     6",
"    </a>",
"    ]. Those who are not sufficiently challenged may develop maladaptive behaviors, mental health conditions (eg, depression),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    academic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Lack of challenge can inhibit the development of self-confidence that comes from mastering difficult material and can lead to poor study habits, which may be difficult to overcome in higher education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the variety of ways in which students can be gifted and the range of domain-specific abilities within a given student, educational interventions and strategies to challenge gifted students must be determined on a case by case basis. The &ldquo;optimal match&rdquo; is a curriculum that matches the child&rsquo;s cognitive abilities, maturity, and academic interests and is sufficiently challenging that it requires the child to work to succeed, but not so challenging that he or she becomes discouraged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors to be considered in choosing an educational program include the student&rsquo;s pattern of strengths and weaknesses, the student&rsquo;s social and emotional maturity, the types of programming available through the local school system, the availability of programs outside of the school setting, and family resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/11\">",
"     11",
"    </a>",
"    ]. The ultimate decision may represent a compromise based on the advantages and disadvantages of the available options.",
"   </p>",
"   <p>",
"    There are few high-quality studies evaluating educational interventions or strategies for gifted children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/12\">",
"     12",
"    </a>",
"    ]. Educational practices that are used for gifted children have influenced general education practices, and in some cases may have been derived from special education. As such, educational practices that are useful for gifted children are useful for a wide range of students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. These practices include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recognition of individual differences",
"     </li>",
"     <li>",
"      Focusing on concepts rather than learning a skill",
"     </li>",
"     <li>",
"      Using an interdisciplinary curriculum and theme-based studies",
"     </li>",
"     <li>",
"      Using alternative methods of assessment (eg, student portfolios or performance assessment)",
"     </li>",
"     <li>",
"      Using peers for teaching and learning",
"     </li>",
"     <li>",
"      Problem-based learning emphasizing metacognition (ie, the use of general or prior knowledge and skills to address new learning problems)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines for the education of gifted students suggest that such students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Be provided with acceleration and enrichment experiences or activities",
"     </li>",
"     <li>",
"      Spend the majority of their school day with others of similar abilities and interests, whether this is part of a high ability group within their grade, or in a higher grade",
"     </li>",
"     <li>",
"      Can be grouped with students not functioning at the same ability level, but primarily for non-academic portions of the school day",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184758813\">",
"    <span class=\"h2\">",
"     Availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The educational opportunities available for gifted students vary from community to community [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7,18,19\">",
"     7,18,19",
"    </a>",
"    ]. Programs and services for students are determined by state laws and policies and are funded at the state and local level. There is wide variation in funding and eligibility definitions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,18,19\">",
"     6,18,19",
"    </a>",
"    ]. Gifted programming may not be a priority in low-income communities or in communities where education is not valued. In such communities, gifted programming may not be offered by the local school district, even though students in that district may be in need of gifted programming.",
"   </p>",
"   <p>",
"    In the United States, information about educational options for gifted children in a given state is available from the state&rsquo;s Department of Education Web site or local school boards and special education departments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/20\">",
"     20",
"    </a>",
"    ]. Individual state board of education definitions for giftedness are available through the",
"    <a class=\"external\" href=\"file://www.nagc.org/GiftedByState.aspx\">",
"     National Association for Gifted Children",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184758722\">",
"    <span class=\"h2\">",
"     Types of intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Programming for children with school-house (ie, academic or intellectual) giftedness must be determined on a case-by-case basis. Specific types of educational interventions or strategies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acceleration",
"     </li>",
"     <li>",
"      Enrichment",
"     </li>",
"     <li>",
"      Ability grouping",
"     </li>",
"     <li>",
"      Programs focusing on meta-cognitive skills and self-regulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These interventions may overlap (ie, a program can be accelerated and enriched) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence about the relative merits of different types of programming is largely inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in experimental and controlled studies, acceleration and enrichment have been beneficial in increasing academic achievement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/11,23-25\">",
"     11,23-25",
"    </a>",
"    ]. The gifted learner typically benefits most from both acceleration and enrichment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753913\">",
"    <span class=\"h3\">",
"     Acceleration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acceleration is the practice of allowing the gifted student to learn at his or her own pace. It can occur for one or multiple academic areas and with or without advanced grade placement. With accelerated programming, the usual curriculum may be taught at a faster pace or the student may be permitted to skip formal instruction on the material that he or she already knows. The student may be placed in a higher grade for one or several classes, may be allowed to skip a grade, or may be allowed to complete coursework in less time than it takes other students (eg, to complete high school in less than the typical four years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acceleration assumes that gifted children learn faster than their peers, but that they learn in the same way (ie, that they are qualitatively similar). This question remains open [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/26\">",
"     26",
"    </a>",
"    ]. Nevertheless, in experimental and controlled studies, acceleration has been associated with improvement in educational progress (sustained interest and involvement in academic activities with high-levels of academic success) of gifted students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,23,27,28\">",
"     6,23,27,28",
"    </a>",
"    ]. Acceleration also may raise educational standards for non-gifted students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/14,29\">",
"     14,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are concerns that acceleration may affect the student&rsquo;s social adjustment and that the student may fail to participate in extracurricular activities with classmates who are chronologically older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/11\">",
"     11",
"    </a>",
"    ]. However, there is no evidence that acceleration is detrimental to the social or emotional adjustment of gifted students when the acceleration is well-planned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/10,28,30\">",
"     10,28,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors to be considered in determining whether acceleration should be undertaken for an individual student include intelligence quotient (IQ), academic skill level (eg, it should be above the mean of the desired grade level), social and emotional maturity to interact with older peers, and whether the child is receptive to acceleration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/10\">",
"     10",
"    </a>",
"    ]. Information about the policies regarding acceleration in individual states of the United States is available through the",
"    <a class=\"external\" href=\"file://www.accelerationinstitute.org/Resources/Policy/By_State/Default.aspx\">",
"     Institute for Research and Policy on Acceleration",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753920\">",
"    <span class=\"h4\">",
"     Grade skipping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grade skipping (also known as double-promotion) is a broad-based form of acceleration that does not take into account the student&rsquo;s specific pattern of abilities or the possibility that gifted and nongifted students learn in different ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/21\">",
"     21",
"    </a>",
"    ]. Advanced grade placement without other interventions does not guarantee an appropriate educational experience.",
"   </p>",
"   <p>",
"    The major concern with grade-skipping is that it places gifted students with students who are physically more advanced and also may be different socially and emotionally. Grade skipping is often avoided for fear of causing social maladjustment. Research findings about social maladjustment are mixed, but suggest that decisions about grade-skipping should be made on case-by-case basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/21\">",
"     21",
"    </a>",
"    ]. Grade skipping may be an option for a moderately gifted student who is a rapid learner with a good memory, but should probably be avoided for profoundly gifted students who would need to be placed with children significantly more advanced in age in order to match their intellectual skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753927\">",
"    <span class=\"h3\">",
"     Enrichment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enrichment is the practice of increasing the depth and breadth of content. Enrichment can occur by providing higher-level texts or exposure to other media that explore the topic in greater depth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    make connections to other disciplines. Enrichment may consist of increasing the knowledge content for the student, allowing the student to participate in special projects related to the course (eg, reports, presentations), or teaching the student creative or other critical thinking skills that may or may not be related to the course content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enrichment can be beneficial to various students, not just those who are gifted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, it may not be appropriate for students who are markedly advanced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/11\">",
"     11",
"    </a>",
"    ]. Asking such students to complete additional work at the same level of difficulty does not enhance growth, teach perseverance, require the development of study skills, or combat boredom.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753934\">",
"    <span class=\"h3\">",
"     Ability grouping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ability grouping refers to using test scores or other measures of achievement to assign students with similar abilities to learning groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6\">",
"     6",
"    </a>",
"    ]. Students of similar abilities can be placed in self-contained classrooms for gifted students, grouped together within a classroom (or across grades) for specific subjects, or attend schools designed for gifted students (eg, magnet schools, science and math schools, private schools that require achievement or IQ testing for admission) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,21\">",
"     6,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ability grouping has not been studied sufficiently to draw firm conclusions. In meta-analyses of evaluations of self-contained classes for gifted children, ability grouping without curriculum modifications (eg, enrichment or acceleration) resulted in minimal or no gains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]. Simply learning alongside peers of similar ability does not provide the stimulation needed by the gifted child. However, when combined with appropriate curriculum modifications, ability grouping was associated with improved performance on standardized tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/27\">",
"     27",
"    </a>",
"    ]. Ability grouping within the classroom does not appear to affect the educational outcomes of students who are not placed in the high-ability group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H184753913\">",
"     'Acceleration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H184753927\">",
"     'Enrichment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ability grouping must be distinguished from &ldquo;cooperative learning&rdquo;. Cooperative learning places students into groups without regard to ability. It is commonly used in general education. Cooperative learning may not be effective for gifted students if the peer group is at a different ability level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/25\">",
"     25",
"    </a>",
"    ]. Gifted students can become bored or domineering when placed alongside less able peers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753941\">",
"    <span class=\"h4\">",
"     Out-of-school programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some programs for gifted children occur outside of the regular classroom. Programs for gifted students may meet on weekends or during the summer. Such programs are a type of ability grouping because the classes are only open to gifted students, who may qualify through a &ldquo;talent search&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/21\">",
"     21",
"    </a>",
"    ]. Acceleration, enrichment, or a combination of both can be used in these out-of-school programs. Out-of-school programs may or may not connect with the student&rsquo;s experience during the academic year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H184753913\">",
"     'Acceleration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H184753927\">",
"     'Enrichment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753948\">",
"    <span class=\"h3\">",
"     Meta-cognitive skills and self-regulated learning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacognitive skills and self-regulated learning are additional approaches that may be of value for some gifted students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,21,32-35\">",
"     6,21,32-35",
"    </a>",
"    ]. Meta-cognitive skills use prior knowledge, or knowledge from several disciplines, to solve complex and novel problems. Self-regulated learning skills are the skills required by students to plan, monitor, and evaluate their own learning. The student is taught to become aware of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    attitude towards learning (curiosity, persistence, self-confidence), and develop the skills of choosing",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own goals, planning the steps needed to reach the goal, and verifying success in executing the plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3506550\">",
"    <span class=\"h3\">",
"     Social and emotional development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educational programming for gifted children can address social and emotional development through [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ensuring time to learn with others of similar abilities",
"     </li>",
"     <li>",
"      Providing opportunities to explore areas of interest with a variety of peers",
"     </li>",
"     <li>",
"      Provision of mentoring or coaching to cope with the stress, criticism, and the social demands of high achievement",
"     </li>",
"     <li>",
"      Developing approaches to help gifted students support one another (eg, group interventions that provide direct instruction in conflict resolution, decision making, and leadership)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753955\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753962\">",
"    <span class=\"h3\">",
"     Profoundly gifted",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profoundly gifted students may be under-challenged even in a gifted program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/11,21,36\">",
"     11,21,36",
"    </a>",
"    ]. They may not find their appropriate level of challenge until they reach college. Grade skipping generally should probably be avoided for profoundly gifted students who would need to be placed with significantly older peers in order to match their intellectual skills. (See",
"    <a class=\"local\" href=\"#H184753920\">",
"     'Grade skipping'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753969\">",
"    <span class=\"h3\">",
"     Gifted with learning disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Services for students who are gifted and also have a learning disability (LD) ideally should include a combination of enrichment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acceleration in the academic area of strength and remediation (eg, special education services) for the areas of weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/37\">",
"     37",
"    </a>",
"    ]. This may result in grade level asynchronies within the student&rsquo;s educational program. (See",
"    <a class=\"local\" href=\"#H184753913\">",
"     'Acceleration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H184753927\">",
"     'Enrichment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37306?source=see_link&amp;anchor=H11284731#H11284731\">",
"     \"Specific learning disabilities in children: Educational management\", section on 'Quality instruction for LD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The accommodations and interventions for LD that are available through special education should be made available to the gifted student with LD, but only if the developmental demands in the areas of weakness are appropriate to the student&rsquo;s ability level. As an example, it may not be appropriate to place a gifted student who has LD into a class for students with LD, because the gifted-LD student may perform better than the nongifted-LD students. The gifted-LD student may best be served by providing supports and services in a general education setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37306?source=see_link\">",
"     \"Specific learning disabilities in children: Educational management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gifted-LD children may not qualify for special education services if the school does not recognize their area(s) of weakness as a LD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/38\">",
"     38",
"    </a>",
"    ]. This may occur if the child&rsquo;s level of function is within the average range for his or her age or grade, even if it is substantially lower than his or her general cognitive ability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link&amp;anchor=H25#H25\">",
"     \"Specific learning disabilities in children: Evaluation\", section on 'Determination of service eligibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of educational interventions for gifted students with coexisting LD is beyond the scope of this topic review, but can be found in the following references [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/3,37,39\">",
"     3,37,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753976\">",
"    <span class=\"h1\">",
"     NONSCHOOL-HOUSE GIFTEDNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature provides little guidance about how to address the needs of children who are gifted in nonacademic domains. Giftedness in areas such as art, music, athletics, and other domains generally is addressed by professionals trained in these domains. The approach for a particular child will vary depending upon the professional who takes on the mentoring or teaching role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184753990\">",
"    <span class=\"h1\">",
"     ROLE OF THE PRIMARY CARE PROVIDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary care provider can play an important role in identifying giftedness and coexisting conditions and providing anticipatory guidance and support to families with a gifted child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This section will focus on the provision of anticipatory guidance and support. The role of the primary care provider in identification of giftedness is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H708854550#H708854550\">",
"     \"The gifted child: Characteristics and identification\", section on 'Role of the primary care provider'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gifted children, particularly profoundly gifted children pose special challenges to families. The demands of caring for a gifted child can, at times, be similar to those of caring for a child with a disability. The primary care provider can support the family by providing anticipatory guidance to promote a healthy balance for the family as a whole, monitoring the gifted child for specific vulnerabilities, and helping the family find appropriate educational programming for their child.",
"   </p>",
"   <p>",
"    The primary care provider&rsquo;s awareness of the special concerns of gifted children and their families can help gifted children to succeed. Like all children, gifted children are more likely to succeed if their needs are understood and addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184754004\">",
"    <span class=\"h2\">",
"     Anticipatory guidance",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184754011\">",
"    <span class=\"h3\">",
"     For the child",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for the primary care provider to help the gifted child to understand how he or she is different from other children and to value those differences. Nonetheless, gifted children should understand that they are expected to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete activities of daily life and respect and follow the household&rsquo;s rules of conduct",
"     </li>",
"     <li>",
"      Have friends and have fun",
"     </li>",
"     <li>",
"      Perform well at school, both in terms of academic function and classroom participation behaviors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184754018\">",
"    <span class=\"h3\">",
"     For the family",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families play a central role in developing the talents of a gifted child; they serve as the child&rsquo;s initial teachers and can nurture the child&rsquo;s curiosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7\">",
"     7",
"    </a>",
"    ]. However, fostering the abilities of gifted children may require time, energy, and financial resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Families may feel pressured to provide enriched experiences and burdened by time and financial commitments. Parenting and living with a gifted child can be challenging, particularly if the child has a coexisting condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/25\">",
"     25",
"    </a>",
"    ]. The pressures on the gifted child to succeed can be a significant stressor for the family. Siblings of the gifted child may receive less attention from the parents.",
"   </p>",
"   <p>",
"    Families may need guidance about how to manage the differences imposed by giftedness, and to normalize their experience of feeling inadequate to the task of raising a gifted child. The parents may not feel prepared to address the child&rsquo;s asynchronous development, internal drive, perfectionism, questioning authority, or atypical social preferences. The primary care provider can provide information and anticipatory guidance to help with these challenges.",
"   </p>",
"   <p>",
"    Important aspects of anticipatory guidance for parents and siblings of gifted children include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/10,11,20\">",
"     10,11,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provision of information about identification practices, educational, and programming options (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H708855915#H708855915\">",
"       \"The gifted child: Characteristics and identification\", section on 'Identification'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H184758722\">",
"       'Types of intervention'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Demystification of giftedness",
"     </li>",
"     <li>",
"      Assurance that most gifted children have good psychosocial adjustment (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H559401957#H559401957\">",
"       \"The gifted child: Characteristics and identification\", section on 'Emotional characteristics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Guidance about how to manage the differences imposed by giftedness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asynchronous development",
"     </li>",
"     <li>",
"      Internal drive (eg, wanting to spend excessive time on areas of interest); the parents can set time limits to help the child balance the area of interest with other important aspects of childhood (eg, having friends and having fun)",
"     </li>",
"     <li>",
"      Perfectionism and its attendant frustration (encourage them to help the child set realistic goals, focus on the process rather than the outcome, and to value the lessons learned from their mistakes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,40\">",
"       6,40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Atypical social preferences (eg, older children, adults); contact with other gifted children of the same age is a major benefit of special programs for gifted children (see",
"      <a class=\"local\" href=\"#H3506550\">",
"       'Social and emotional development'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      More frequent questioning of authority; when the parent&rsquo;s authority is questioned,",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      can respond with something like: &ldquo;I have to do my job. My job is to make sure that you perform well in all areas of life, not just those that you prefer.&rdquo; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Letting them know that it is normal to feel inadequate or ill-equipped to raise a gifted child; there is no single best way to raise a gifted child as long as the parents set clear and high expectations and are invested and responsive (eg, respect the child&rsquo;s questions, provide interesting experiences, etc) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,41\">",
"       6,41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Helping them avoid resentment of the gifted child by his or her nongifted siblings (by encouraging them to consider each of their children unique, with individual strengths and weaknesses rather than",
"      <span class=\"nowrap\">",
"       gifted/not",
"      </span>",
"      gifted and encouraging them to spend designated special time with each child)",
"     </li>",
"     <li>",
"      Helping them to understand that, despite their differences, gifted children should be expected to participate in family and community life, to respect household rules, to participate in tasks, chores, etc. This is true no matter how much time is dedicated to talent development or how sophisticated the child is at arguing that they need not comply with ordinary rules of conduct",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H385322210\">",
"    <span class=\"h3\">",
"     Assessing program quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following questions can help parents assess the child&rsquo;s current programming, and help decide if evaluation and specialized or gifted programming is needed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does the child enjoy school?",
"     </li>",
"     <li>",
"      Is the child learning new information, or simply repeating topics already mastered?",
"     </li>",
"     <li>",
"      Are academic strengths as well as weaknesses noticed in the student?",
"     </li>",
"     <li>",
"      Does the teacher know the child, and does the teacher know what the child can really do?",
"     </li>",
"     <li>",
"      Is the school able to be flexible in matching educational programs to the child&rsquo;s interests and needs?",
"     </li>",
"     <li>",
"      Does the school offer educational acceleration, enrichment, or ability grouping?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184754025\">",
"    <span class=\"h2\">",
"     Monitoring for vulnerabilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although gifted children generally have good emotional adjustment, they have particular areas of emotional vulnerability. It is important for the primary care provider to monitor for these problems and make referrals to mental health providers as necessary.",
"   </p>",
"   <p>",
"    These vulnerabilities include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,7,40\">",
"     6,7,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity, emotional intensity, loneliness and social isolation (particularly for those with intelligence quotient &gt;160) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H559401965#H559401965\">",
"       \"The gifted child: Characteristics and identification\", section on 'Social characteristics'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maladaptive perfectionism, which may lead to anxiety, or depression (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H559401957#H559401957\">",
"       \"The gifted child: Characteristics and identification\", section on 'Emotional characteristics'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Asynchronous development in social, emotional, and intellectual domains (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H559401950#H559401950\">",
"       \"The gifted child: Characteristics and identification\", section on 'Developmental characteristics'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maladaptive behaviors and academic failure if not sufficiently challenged and supported (see",
"      <a class=\"local\" href=\"#H184758616\">",
"       'Overview'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about balancing psychosocial health with giftedness is available in reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184754032\">",
"    <span class=\"h2\">",
"     Advocacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary care provider may be able to provide information or resources about programs to help the gifted student explore his or her interests in greater depth and to interact with peers who have similar interests and abilities. (See",
"    <a class=\"local\" href=\"#H3507528\">",
"     'Resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Practitioners who are familiar with local school districts and programs may be able to help parents negotiate with school personnel to determine the optimum interventions for their child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3507380\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal studies of children identified as intellectually advanced in elementary school indicate that, as a group, they continue to achieve at relatively high levels of competence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7\">",
"     7",
"    </a>",
"    ]. However, there is individual variation. Opportunities for education and mentoring, socioeconomic conditions, individual social skills and motivation, and participation in talent development programs may affect long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/21,43,44\">",
"     21,43,44",
"    </a>",
"    ]. In observational studies, higher achievement appears to be associated with high and clear parental expectations and a flexible but firm parenting style [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/6,41\">",
"     6,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most gifted children do well as adults. However, they do not necessarily make major contributions to their particular domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/44\">",
"     44",
"    </a>",
"    ]. Above the level of 120, intelligence quotient appears not to predict adult eminence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gifted students can and do drop out of school. The number of gifted students who drop out is unclear because of the limited number of quality studies and the varying definitions of giftedness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/46\">",
"     46",
"    </a>",
"    ]. However, gifted students may be over-represented among high school dropouts. In one study of gifted high school drop-outs, the reasons for dropping out varied, but not liking school was a major factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term course of nonschool-house talents (eg, music, chess, athletics) is variable. It depends upon the social value placed upon the talent, opportunities for expert instruction, and the child&rsquo;s dedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3507528\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources for clinicians and families are provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef83644 \" href=\"mobipreview.htm?19/16/19725\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184759154\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gifted individuals have exceptional abilities in a particular domain or domains (eg, mathematics, music, athletics). The United States Department of Education definition for giftedness (",
"      <a class=\"graphic graphic_table graphicRef83643 \" href=\"mobipreview.htm?31/13/31963\">",
"       table 1",
"      </a>",
"      ) is the most widely accepted by researchers and practitioners in the field of giftedness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H6676580#H6676580\">",
"       \"The gifted child: Characteristics and identification\", section on 'Introduction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=see_link&amp;anchor=H370340910#H370340910\">",
"       \"The gifted child: Characteristics and identification\", section on 'Terminology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The development of giftedness is a long-term endeavor, fostered by early identification, supportive and encouraging parents, and teachers and mentors who place high expectations on the student. Gifted students need to be challenged to maintain interest and high achievement. Those who are not sufficiently challenged may develop maladaptive behaviors, mental health conditions (eg, depression),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      academic failure. Lack of challenge can inhibit the development of self-confidence and lead to poor study habits. (See",
"      <a class=\"local\" href=\"#H184758616\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The educational opportunities available for gifted students vary from community to community. (See",
"      <a class=\"local\" href=\"#H184758813\">",
"       'Availability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Educational programming for children with school-house (ie, academic or intellectual) giftedness is best determined on a case-by-case basis. In experimental and controlled studies, acceleration and enrichment have been beneficial in increasing academic achievement. (See",
"      <a class=\"local\" href=\"#H184758722\">",
"       'Types of intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Services for students who are gifted and also have a learning disability ideally should include a combination of enrichment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acceleration in the academic area of strength and remediation for the areas of weakness. (See",
"      <a class=\"local\" href=\"#H184753969\">",
"       'Gifted with learning disability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Giftedness in areas such as art, music, athletics, and other domains generally is addressed by professionals trained in these domains. The approach for a particular child will vary depending upon the professional who takes on the mentoring or teaching role. (See",
"      <a class=\"local\" href=\"#H184753976\">",
"       'Nonschool-house giftedness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary care provider can play an important role in providing anticipatory guidance and support to the gifted child and his or her family. The primary care provider also can monitor the gifted child for vulnerabilities associated with giftedness. (See",
"      <a class=\"local\" href=\"#H184753990\">",
"       'Role of the primary care provider'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Longitudinal studies of children identified as intellectually advanced in elementary school indicate that, as a group, they continue to achieve at relatively high levels of competence. However, there is individual variation. (See",
"      <a class=\"local\" href=\"#H3507380\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184754046\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author wishes to acknowledge James T Webb, PhD (founder of Supporting Emotional Needs of the Gifted [SENG] and former professor and associate Dean, School of Professional Psychology, Wright State University, Dayton, OH) and Marianne Kuzujanakis, MD (Director, SENG) for their valuable contributions to this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/1\">",
"      Landesman S. Defining giftedness. Pediatr Ann 1985; 14:698.",
"     </a>",
"    </li>",
"    <li>",
"     National Excellence: A case for developing America's talent. 1993. file://www.eric.ed.gov/PDFS/ED359743.pdf (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     National Association for Gifted Children Position Paper: Redefining Giftedness for a New Century: Shifting the Paradigm. March 2010. Available at: www.nagc.org/index2.aspx?id=6404 (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     National Association for Gifted Children. Gifted in the States. file://www.nagc.org/GiftedByState.aspx (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/5\">",
"      Feldhusen JF. Giftedness. Parents and schools should provide for gifted children. BMJ 1993; 307:1088.",
"     </a>",
"    </li>",
"    <li>",
"     Kral MC. The gifted child. In: Developmental-Behavioral Pediatrics, Carey WB, Crocker AC, Coleman WL, et al.  (Eds), Saunders-Elsevier, Philadelphia 2009. p.506.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/7\">",
"      Robinson NM, Olszewski-Kubilius PM. Gifted and talented children: issues for pediatricians. Pediatr Rev 1996; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/8\">",
"      Reis SM, McCoach DB. The underachievement of gifted students: What do we know and where do we go? Gift Child Q 2000; 44:152.",
"     </a>",
"    </li>",
"    <li>",
"     Siegle D, McCoach DM. Issues related to the underachievement of gifted students. In: Leading Change in Gifted Education: The Festschrift of Dr. Joyce Vantassel-Baska, McFarlane B, Stambaugh T.  (Eds), Prufrock Press Inc, Waco, TX 2009. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/10\">",
"      Pfeiffer SI. The gifted: clinical challenges for child psychiatry. J Am Acad Child Adolesc Psychiatry 2009; 48:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/11\">",
"      Robinson NM. Educational options for gifted children. Pediatr Ann 1985; 14:745, 747, 750 passim.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/12\">",
"      Ziegler A, Raul T. Myth and reality: A review of empirical studies on giftedness. High Ability Studies 2000; 11:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/13\">",
"      Gallagher JJ. Unthinkable thoughts: Education of gifted students. Gift Child Q 2000; 44:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/14\">",
"      Renzulli JS. Applying gifted education pedagogy to total talent development for all students. Theory Into Practice 2005; 44:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/15\">",
"      Grant B. Justifying gifted education: A critique of needs claims and a proposal. Journal of Education for the Gifted 2002; 25:359.",
"     </a>",
"    </li>",
"    <li>",
"     Rogers KB. Re-Forming Gifted Education: How Parents and Teachers Can Match the Program to the Child, The National Research Center on the Gifted and Talented, University of Connecticut, Storrs, CT 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/17\">",
"      Shore BM, Delcourt MA. Effective Curricular and Program Practices in Gifted Education and the Interface with General Education. Journal for the Education of the Gifted 1996; 20:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/18\">",
"      Swiatek MA, Lupkowski-Shoplik A. Elementary and middle school participation in gifted programs: Are gifted students underserved? Gift Child Q 2003; 47:118.",
"     </a>",
"    </li>",
"    <li>",
"     Davidson Institute for Talent Development. Available at: file://www.davidsongifted.org/ (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     Rock M. The gifted child. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd, Augustyn MA, Zuckerman B, Caronna EB.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.234.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/21\">",
"      Winner E. Exceptionally high intelligence and schooling. Am Psychol 1997; 52:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/22\">",
"      Freeman J. Teaching gifted pupils. J Biol Educ 1999; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     Colangelo N, Assouline S, Gross M. A Nation Deceived: How schools hold back America&rsquo;s Brightest Students file://www.accelerationinstitute.org/Nation_Deceived/Get_Report.aspx (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     Rogers KB. Program provisions (grouping) within the school. In: Re-Forming Gifted Education: How Parents and Teachers Can Match the Program to the Child, The National Research Center on the Gifted and Talented, University of Connecticut, Storrs, CT 2002. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/25\">",
"      Robinson A, Clinkenbeard PR. Giftedness: an exceptionality examined. Annu Rev Psychol 1998; 49:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/26\">",
"      Winner E. Giftedness: Current Theory and Research. Curr Dir Psychol Sci 2000; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/27\">",
"      Kulik JA, Kulik CC. Meta-analytic findings on grouping programs. Gift Child Q 1992; 36:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/28\">",
"      Gross MU, van Vliet HE. Radical acceleration and early entry to college: A review of the research. Gift Child Q 2005; 49:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/29\">",
"      Ma X. A longitudinal assessment of early acceleration of students in mathematics on growth in mathematics achievement. Developmental Review 2005; 25:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/30\">",
"      Gagne F, Gagnier N. The socio-affective and academic impact of early entrance to school. Roeper Rev 2004; 26:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/31\">",
"      Slavin RE. Achievement effects of ability grouping in secondary schools: A best-evidence synthesis. Review of Educational Research 1990; 60:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/32\">",
"      Liu YH, Lien J, Kafka T, Stein MT. Discovering gifted children in pediatric practice. J Dev Behav Pediatr 2005; 26:366.",
"     </a>",
"    </li>",
"    <li>",
"     Shore BM, Kanevsky LS. Thinking processes: Being and becoming gifted. In: International Handbook of Research and Development of and Talent, Heller KA, Monks FJ, Passow AH (Eds), Pergamon, Oxford, UK 1993. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/34\">",
"      Hannah CL, Shore BM. Metacognition and high intellectual ability: Insights from the study of learning-disabled gifted students. Gift Child Q 1995; 39:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/35\">",
"      Freeman J. Teaching gifted pupils. J Biol Educ 1999; 34:185.",
"     </a>",
"    </li>",
"    <li>",
"     Winner E. Gifted Children: Myths and Realities, Basic Books, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/37\">",
"      Volker MA, Lopata C, Cook-Cottone C. Assessment of children with intellectual giftedness and reading disabilities. Psychol Sch 2006; 43:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/38\">",
"      McCoach DB, Kehle TJ, Bray MA, Siegle D. Best Practices in the Identification of Gifted Students with Learning Disabilities. Psychol Sch 2001; 38:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/39\">",
"      Baum SM, Cooper CR, Neu TW. Dual differentiation: An approach for meeting the curricular needs of gifted students with learning disabilities. Psychol Sch 2001; 38:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/40\">",
"      Schuler PA. Perfectionism and the gifted adolescent. J Secondary Gifted Educ 2000; 11:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/41\">",
"      Neihart M. Dimensions of underachievement, difficult contexts, and perceptions of self. Roeper Rev 2006; 28:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/42\">",
"      Moon SM, Hall AS. Family therapy with intellectually and creatively gifted children. J Marital Fam Ther 1998; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/43\">",
"      Gagn&eacute; F. Transforming gifts into talents: The DMGT as a developmental theory. High Ability Studies 2004; 15:119.",
"     </a>",
"    </li>",
"    <li>",
"     Beyond Terman: Contemporary Longitudinal Studies of Giftedness and Talent, Ablex Publishing, Norwood, NJ 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/45\">",
"      Barron F, Harrington DM. Creativity, intelligence, and personality. Ann Rev Psychol 1981; 32:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33240/abstract/46\">",
"      Renzulli JS, Park S. Gifted dropouts: The who and the why. Gift Child Q 2000; 40:261.",
"     </a>",
"    </li>",
"    <li>",
"     Renzulli JS, Park S. Giftedness and high school dropouts: Personal, family, and school-related factors. National Research Center on the Gifted and Talented. December 2002. Available at: file://www.myextgted.uconn.edu/nrcgt/renzpark.html (Accessed on May 09, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83538 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33240=[""].join("\n");
var outline_f32_29_33240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H184759154\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184755606\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H466903174\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184753906\">",
"      SCHOOL-HOUSE GIFTEDNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184758616\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184758813\">",
"      Availability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184758722\">",
"      Types of intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184753913\">",
"      - Acceleration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H184753920\">",
"      Grade skipping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184753927\">",
"      - Enrichment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184753934\">",
"      - Ability grouping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H184753941\">",
"      Out-of-school programs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184753948\">",
"      - Meta-cognitive skills and self-regulated learning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3506550\">",
"      - Social and emotional development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184753955\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184753962\">",
"      - Profoundly gifted",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184753969\">",
"      - Gifted with learning disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184753976\">",
"      NONSCHOOL-HOUSE GIFTEDNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184753990\">",
"      ROLE OF THE PRIMARY CARE PROVIDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184754004\">",
"      Anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184754011\">",
"      - For the child",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184754018\">",
"      - For the family",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H385322210\">",
"      - Assessing program quality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184754025\">",
"      Monitoring for vulnerabilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184754032\">",
"      Advocacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3507380\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3507528\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184759154\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184754046\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/83538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/13/31963\" title=\"table 1\">",
"      Giftedness definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/16/19725\" title=\"table 2\">",
"      Giftedness resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37306?source=related_link\">",
"      Specific learning disabilities in children: Educational management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=related_link\">",
"      Specific learning disabilities in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/33/17944?source=related_link\">",
"      The gifted child: Characteristics and identification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_29_33241="Screening guidelines for dyslipidemia";
var content_f32_29_33241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening guidelines for dyslipidemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33241/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33241/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33241/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33241/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/29/33241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for screening for a dyslipidemia rests upon several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypercholesterolemia and coronary heart disease (CHD) are common in industrialized societies",
"     </li>",
"     <li>",
"      There is a direct relation between the plasma levels of total and low density lipoprotein (LDL) plasma cholesterol and the risk of CHD and coronary mortality",
"     </li>",
"     <li>",
"      LDL cholesterol lowering in moderate to high-risk patients leads to a reduction in cardiovascular events",
"     </li>",
"     <li>",
"      Abnormalities of plasma lipids (dyslipidemia) other than LDL cholesterol are common in patients with early onset CHD",
"     </li>",
"     <li>",
"      HDL cholesterol levels are related to absolute CHD event rates in treated hypercholesterolemic subjects with and without baseline clinical CHD",
"     </li>",
"     <li>",
"      Screening tests for dyslipidemia are widely available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issues surrounding cholesterol screening are reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment guidelines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart disease mortality has declined steadily since the 1960s, but CHD remains the leading cause of death for both men and women of all races and ethnicities in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/2\">",
"     2",
"    </a>",
"    ]. A large proportion of elderly individuals will suffer from CHD. In men over the age of 65, for example, nearly one-half of all deaths are attributed to CHD, compared to less than 25 percent for all cancers and less than 2 percent for all infections. An even higher proportion of deaths are due to CHD in older women (56 percent), with less than 20 percent due to cancer.",
"   </p>",
"   <p>",
"    A variety of factors, often acting in concert, are associated with an increased risk for atherosclerotic plaques in coronary arteries and other arterial beds (",
"    <a class=\"graphic graphic_figure graphicRef55353 \" href=\"mobipreview.htm?24/31/25086\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Hypercholesterolemia is one of the major modifiable risk factors for CHD, even in those over the age of 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of dyslipidemia varies with the population studied and the definition of dyslipidemia. The incidence is highest in patients with premature CHD, which is defined as clinically evident disease occurring before 55 years of age in men and before 65 years in women. In this setting, the prevalence of dyslipidemia is as high as 80 to 88 percent compared to approximately 40 to 48 percent in age-matched controls without coronary disease (",
"    <a class=\"graphic graphic_figure graphicRef59944 \" href=\"mobipreview.htm?15/40/16014\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/6\">",
"     6",
"    </a>",
"    ]. The mean serum total cholesterol concentration of the adult United States (US) population showed a small decline in 1999 to 2002 compared with that found in 1988 to 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/7\">",
"     7",
"    </a>",
"    ]. Over the same periods, the percentage of US adults with a total cholesterol level of 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.22",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or higher declined from 20 to 17 percent. The proportion of US adults either on treatment for cholesterol elevation or with elevated LDL-cholesterol levels changed little between the period from 1999 to 2002 and the period from 2005 to 2008, however the proportion whose LDL-C was below ATP-III goal (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link&amp;anchor=H2#H2\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\", section on 'Identification of patients at risk'",
"    </a>",
"    ) increased from 28 to 48 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Global total cholesterol levels have changed little since 1980 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/9\">",
"     9",
"    </a>",
"    ]. In 2008, the mean worldwide age-standardized total cholesterol level was 179",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.64",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in men and 184",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.76",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in women, a decline of 3.1",
"    <span class=\"nowrap\">",
"     mg/dL/decade",
"    </span>",
"    (0.08",
"    <span class=\"nowrap\">",
"     mmol/L/decade)",
"    </span>",
"    since 1980. There was regional variation, with some regions experiencing small declines and others small increases in mean total cholesterol; despite small declines in the high-income regions (Australasia, North America, Western Europe), these were the areas with the highest absolute mean total cholesterol levels in 2008.",
"   </p>",
"   <p>",
"    One definition of dyslipidemia is serum total cholesterol, LDL-cholesterol, triglyceride, apo-B, or Lp(a) concentrations above the ninetieth percentile, or HDL-cholesterol or apo A-1 concentrations below the tenth percentile for the general population (",
"    <a class=\"graphic graphic_table graphicRef71803 \" href=\"mobipreview.htm?18/63/19453\">",
"     table 1",
"    </a>",
"    ). A review of lipoprotein metabolism and the function of the different apolipoproteins is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSOCIATION BETWEEN DYSLIPIDEMIA AND CORONARY RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data have documented a continuous, graded relationship between the serum total plasma cholesterol concentration and coronary risk (",
"    <a class=\"graphic graphic_figure graphicRef60146 graphicRef50334 \" href=\"mobipreview.htm?26/27/27070\">",
"     figure 3A-B",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. This is true even for younger men (eg, under the age of 40) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/12\">",
"     12",
"    </a>",
"    ], and in both men and women, cumulative nonoptimal lipid levels at a young age (between ages 18 and 30) are associated with increased coronary calcium 15 to 20 years later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/13\">",
"     13",
"    </a>",
"    ].The causal role of cholesterol in this relationship is suggested by clinical trials which have demonstrated that targeted lowering of cholesterol in patients with hypercholesterolemia reduces CHD morbidity. A meta-analysis of 38 primary and secondary prevention trials, for example, found that for every 10 percent reduction in serum cholesterol, CHD mortality would be reduced by 15 percent and total mortality risk by 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum cholesterol concentration in the blood is comprised of several major fractions, which are categorized according to their relative density. Serum total cholesterol has been used to screen adults at risk for CHD, but more recent data emphasize the advantages in knowing the concentrations of lipid fractions, such as low density lipoprotein (LDL) and high density lipoprotein (HDL).",
"   </p>",
"   <p>",
"    The role of different lipid particles in the development of atherosclerosis and CHD is discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    ). It is useful, however, to summarize the major observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Low density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;High concentrations of LDL are a particularly important risk factor for atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The oxidative modification of LDL appears to be one mechanism by which LDL promotes atherosclerosis; oxidized LDL may lead to atherogenesis via a number of mechanisms (",
"    <a class=\"graphic graphic_table graphicRef51940 \" href=\"mobipreview.htm?1/53/1883\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64231 \" href=\"mobipreview.htm?16/47/17142\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher LDL-cholesterol concentrations have been associated with an increased incidence of CHD in a large number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/19\">",
"     19",
"    </a>",
"    ]. Elevated plasma concentrations of oxidized LDL also are associated with CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LDL-cholesterol levels serve as the primary target of lipid lowering treatment strategies, and it is important to consider the clinical utility of apolipoprotein B or LDL particle concentration measurements for cardiovascular risk assessment and potential therapeutic targets in the primary and secondary prevention of cardiovascular diseases. LDL-cholesterol measurements may provide an inaccurate measure of the number and type of circulating lipoprotein particles for many individuals due to differences in core LDL composition and LDL particle size. When LDL particles are compositionally abnormal, due to decreased size or decreased core cholesterol content, the LDL particle concentration will place the patient within a higher-risk category than indicated by LDL cholesterol concentration. In metabolic syndrome and type 2 diabetes patients, there is a larger discrepancy between LDL cholesterol and LDL particle concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) classified the risk associated with various LDL cholesterol concentrations as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef70489 \" href=\"mobipreview.htm?31/39/32379\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low level of high density lipoprotein (HDL) is another important risk factor for atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/23\">",
"     23",
"    </a>",
"    ]. Comparisons of the lipid profile to coronary angiography have shown an association between low HDL values and anatomic coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low serum HDL (hypoalphalipoproteinemia) is also associated with increased risk of overt CHD (",
"    <a class=\"graphic graphic_table graphicRef57480 \" href=\"mobipreview.htm?0/2/35\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/25\">",
"     25",
"    </a>",
"    ]. Based upon data from the Framingham Heart Study, the risk for myocardial infarction increases by about 25 percent for every 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.13",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    decrement below median values for men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, a high serum HDL (above 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 1.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is cardioprotective (",
"    <a class=\"graphic graphic_table graphicRef57480 \" href=\"mobipreview.htm?0/2/35\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Total cholesterol to HDL ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Lipid Research Clinics and the Framingham Heart Study suggest that the total cholesterol (or LDL-cholesterol) to HDL-cholesterol (HDL-C) ratio may have greater predictive value for CHD than serum total or LDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among men, a ratio of 6.4 or more identified a group at 2 to 14 percent greater risk than predicted from serum total or LDL-cholesterol",
"     </li>",
"     <li>",
"      Among women, a ratio of 5.6 or more identified a group at 25 to 45 percent greater risk than predicted from serum total or LDL-cholesterol",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, serum total or LDL-cholesterol did not add independent predictive value to the ratio.",
"   </p>",
"   <p>",
"    Similarly, a prospective analysis from the Women's Health Study found that the total cholesterol to HDL-C ratio was highly predictive of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/27\">",
"     27",
"    </a>",
"    ]. Comparing women in the highest and lowest quintiles for the ratio, the hazard ratio for an event was 3.8 (95% CI 2.5-5.9). This was superior to the prognostic value of other lipid parameters and ratios including those using apolipoprotein measurements (",
"    <a class=\"graphic graphic_figure graphicRef74969 \" href=\"mobipreview.htm?31/12/31950\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Apolipoproteins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Triglycerides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertriglyceridemia is associated with an increased risk for cardiovascular disease. As an example, in a meta-analysis of prospective population-based studies that evaluated the association between the serum triglyceride concentration and incident cardiovascular disease, pooled analysis of 46,413 men enrolled in 16 studies was associated with a univariate risk ratio (RR) for triglyceride of 1.32 (95% CI 1.26-1.39) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/28\">",
"     28",
"    </a>",
"    ]. The five studies of nearly 10,800 women were associated with a univariate RR of 1.76 (95% CI 1.50-2.07).",
"   </p>",
"   <p>",
"    Hypertriglyceridemia is often associated with reduced levels of HDL-cholesterol. Although the risk ratios for hypertriglyceridemia in both men and women decreased when the HDL cholesterol concentration was included in the analysis, the risk ratios remained significant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An interaction between triglycerides and the total",
"    <span class=\"nowrap\">",
"     cholesterol/HDL-cholesterol",
"    </span>",
"    <span class=\"nowrap\">",
"     (TC/HDL-C)",
"    </span>",
"    ratio has been demonstrated in several studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Physician's Health Study, the risk of myocardial infarction (MI) was highest among men with the highest tertile for both triglyceride and the",
"      <span class=\"nowrap\">",
"       TC/HDL-C",
"      </span>",
"      ratio [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Helsinki Heart Study, CHD risk was highest in the cohort with a triglyceride level &gt;201",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and an",
"      <span class=\"nowrap\">",
"       LDL-cholesterol/HDL-cholesterol",
"      </span>",
"      ratio &gt;5.0 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/30\">",
"       30",
"      </a>",
"      ]. A benefit from lipid-lowering from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      was confined to this high-risk subgroup (",
"      <a class=\"graphic graphic_figure graphicRef67263 \" href=\"mobipreview.htm?6/9/6302\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the Copenhagen Male Study, there was a gradient of CHD risk with increasing serum triglycerides within each tertile of HDL-C, even after adjustment for other major CHD risk factors, including LDL-cholesterol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/31\">",
"       31",
"      </a>",
"      ]. The protective effect of a high HDL-C concentration above 68",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.71",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      was not seen in the highest tertile of triglyceride levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest a possible metabolic interaction between triglycerides and cholesterol ester-rich lipoproteins. In addition, high levels of triglycerides may directly promote atherothrombosis. These concentrations are associated with increases in fibrinogen, clotting factors VII and X, and blood viscosity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Knowing a patient's triglyceride level does not appear to improve the ability to estimate CHD risk beyond the estimate provided by measurement of serum cholesterol subfractions alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/32\">",
"     32",
"    </a>",
"    ]. Nevertheless, because elevated triglycerides are an independent risk factor for CHD, recommendations from ATP III include measurement of triglycerides as part of routine cholesterol screening (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lipoprotein(a)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoprotein (a), also called Lp(a), is an independent risk factor for CHD. In addition strong evidence exists for a causal relationship between Lp(a) and myocardial infarction. The discussion of the role of screening for Lp(a) is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40248?source=see_link&amp;anchor=H13#H13\">",
"     \"Lipoprotein(a) and cardiovascular disease\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-HDL-cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HDL cholesterol is defined as the difference between the total cholesterol and HDL cholesterol. Non-HDL cholesterol includes all cholesterol present in lipoprotein particles that are considered atherogenic, including LDL, lipoprotein(a), intermediate-density lipoprotein, and very-low-density lipoprotein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/1\">",
"     1",
"    </a>",
"    ]. It has been suggested that the non-HDL cholesterol fraction may be a better tool for risk assessment than LDL cholesterol.",
"   </p>",
"   <p>",
"    This issue was evaluated in the Lipid Research Clinics Program, that included a total of 2406 men and 2056 women ages 40 to 64 years at study entry who were followed for an average of 19 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/33\">",
"     33",
"    </a>",
"    ]. The LDL cholesterol fraction was a slightly weaker predictor of cardiovascular death than the non-HDL cholesterol fraction. Differences of 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.78",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in non-HDL cholesterol and LDL cholesterol corresponded to increases in cardiovascular disease mortality of 19 and 15 percent, respectively, in men, and 11 and 8 percent, respectively, in women.",
"   </p>",
"   <p>",
"    An analysis from the Women's Health Study found that non-HDL cholesterol was highly predictive of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/27\">",
"     27",
"    </a>",
"    ]. Comparing women in the highest and lowest quintiles for non-HDL cholesterol, the hazard ratio for an event was 2.5 (95% CI 1.7-3.7). This was equivalent or superior to the prognostic value of other individual lipid parameters including apolipoprotein measurements (",
"    <a class=\"graphic graphic_figure graphicRef74969 \" href=\"mobipreview.htm?31/12/31950\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Apolipoproteins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     LDL subclasses and LDL particle concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL subclasses have been shown to identify CHD patients at higher risk for progression of coronary atherosclerosis. In the Familial Atherosclerosis Treatment Study (FATS), on-trial changes in LDL buoyancy measured by density gradient ultracentrifugation were the most important predictor of coronary progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/34\">",
"     34",
"    </a>",
"    ]. In the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     Pravastatin",
"    </a>",
"    Limitation of Atherosclerosis in the Coronaries (PLAC-I) study, small LDL particle size (&le;20.5 nm) measured by NMR identified subjects at increased rates of coronary progression (odds ratio 5.0, 95% CI 1-9), whereas high numbers of small LDL particles (&gt;30",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    were the most important lipoprotein predictor (odds ratio 9.1, 95% CI 2.1-39) after adjustment for age, gender, other CHD risk factors, and plasma lipids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/35\">",
"     35",
"    </a>",
"    ]. In patients with diabetes, small LDL size was significantly associated with coronary progression in models that included LDL cholesterol, apolipoprotein B, and triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cardiovascular Health Study (CHS) reported that in a multivariate analysis that included standard chemical lipids (triglycerides, LDL cholesterol, and HDL cholesterol) glucose, insulin, waist circumference, and high sensitivity C-reactive protein (hs-CRP), LDL particle concentration but not LDL size was a significant predictor of myocardial infarction and angina in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/37\">",
"     37",
"    </a>",
"    ]. For every 100",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    increase in LDL particle number, the odds of myocardial infarction and angina increased by 11 percent.",
"   </p>",
"   <p>",
"    Case control studies nested within large prospective cohort studies have also examined the prognostic value of LDL particle size and particle concentration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Women's Health Study (WHS) assessed NMR-measured LDL particle size and LDL particle concentration as risk factors for myocardial infarction, stroke, or CHD death in healthy middle-aged women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/38\">",
"       38",
"      </a>",
"      ]. LDL particle concentration and LDL particle size were significant predictors of cardiovascular disease (relative risk for the highest compared with lowest quartile 4.17 [95% CI 1.96-8.87] and 2.04 [CI 1.06-3.94], respectively). LDL particle concentration remained a strong predictor of cardiovascular disease after adjustment for traditional risk factors (body mass index, history of hypertension, history of diabetes, parental history of myocardial infarction, frequency of exercise, and use of hormonal replacement therapy), total cholesterol to HDL cholesterol ratio, triglycerides, and hs-CRP. In contrast, the increased risk associated with small LDL particle size was negated in a multivariate analysis that included LDL particle concentration. These relative risks were compared with LDL cholesterol (2.06 [CI 1.03-4.12]), non-HDL cholesterol (2.94 [CI 1.43-6.05]), and the ratio of total cholesterol to HDL cholesterol (3.11 [95% CI 1.55-6.26]). Levels of apolipoprotein B were associated with an increased risk of 2.43 (CI 2.43-4.82).",
"     </li>",
"     <li>",
"      The European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Prospective Population Study examined NMR-measured LDL particle size and particle concentration as predictors of CHD (hospital admission for CHD or CHD mortality) in healthy men and women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/39\">",
"       39",
"      </a>",
"      ]. In univariate analyses, LDL particle concentration (odds ratio [OR] 2.00, 95% CI 1.58-2.59) was more strongly associated with CHD than LDL-C (OR 1.73), but it was not more strongly associated than non-HDL-C (OR 2.14). In multivariate modeling, once adjustments were made for HDL-C and triglycerides, LDL particle concentration did not increase the predictive value of the model more than LDL-C; after adjusting for LDL particle concentration, LDL size was no longer associated with CHD. This study examined a population with higher LDL-C levels and less obesity than prior studies that had found an incremental risk of LDL particle concentration. Among hypercholesterolemic individuals with a low prevalence of the metabolic syndrome, LDL particle size is larger so that the difference between LDL-C concentration and LDL particle concentration is less.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that NMR-measured LDL particle concentration adds some incremental predictive value above LDL-C, and may be particularly informative in individuals at high cardiometabolic risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Apolipoproteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that measurement of apolipoproteins may be better indicators of the total number of atherogenic particles than the above measures since cholesterol concentrations vary greatly within LDL and HDL because of the lipid-transfer process among lipoproteins. Specifically, measurement of plasma apo B and apo A-1 allow an assessment of the total number of atherogenic (LDL, VLDL, and IDL) and antiatherogenic particles (HDL), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/41-44\">",
"     41-44",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/45\">",
"     45",
"    </a>",
"    ] studies have reported that apo B and apo A-1 are important predictors of CHD risk. The AMORIS study evaluated this relationship prospectively in 175,553 individuals who were followed for a mean of 65 months; measurement of these apolipoproteins improved the prediction of fatal myocardial infarction at all levels of total cholesterol, LDL cholesterol, and triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/42\">",
"     42",
"    </a>",
"    ]. In a multivariate analysis, the concentration of apo B was more highly significant than LDL cholesterol and added predictive power to LDL cholesterol.",
"   </p>",
"   <p>",
"    The Quebec Cardiovascular study demonstrated that small LDL particle diameter was a more important predictor of ischemic heart disease than LDL cholesterol (odds ratio 3.7 [95% CI 1.4-9.7] versus 1.8 [95% CI 1.2-2.9], respectively) after adjustment for diabetes, systolic blood pressure, family history of ischemic heart disease, and medication use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/46\">",
"     46",
"    </a>",
"    ]. However, particle size and increased numbers of atherogenic lipoproteins as estimated by the concentration of apolipoprotein B was the most important predictor of clinical CHD events (odds ratio 6.2, 95% CI 2.2-17.4). In",
"    <span class=\"nowrap\">",
"     AFCAPS/TexCAPS,",
"    </span>",
"    LDL cholesterol was not a significant predictor of events at either baseline or year one; however, on-treatment LDL cholesterol was not related to the primary end point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/47\">",
"     47",
"    </a>",
"    ]. In contrast, on-treatment apolipoprotein B was the strongest single predictor of cardiovascular events, and the importance of apolipoprotein B was only slightly improved by inclusion of apolipoprotein AI as part of the apolipoprotein",
"    <span class=\"nowrap\">",
"     B/AI",
"    </span>",
"    ratio.",
"   </p>",
"   <p>",
"    An analysis from the Women's Health Study found that while apolipoprotein B-100 cholesterol was highly predictive of cardiovascular events, it was highly correlated with the more easily obtained value of non-HDL cholesterol and had similar predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/27\">",
"     27",
"    </a>",
"    ]. The ratio of apolipoprotein B-100 to apolipoprotein AI was inferior in predicting risk to the more easily obtained ratio of total cholesterol to HDL-cholesterol (",
"    <a class=\"graphic graphic_figure graphicRef74969 \" href=\"mobipreview.htm?31/12/31950\">",
"     figure 5",
"    </a>",
"    ). Similarly, an analysis of 3322 participants from the Framingham Study found that the apo",
"    <span class=\"nowrap\">",
"     B/AI",
"    </span>",
"    ratio had similar predictive value to the total cholesterol to HDL-C ratio and did not add incremental value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/48\">",
"     48",
"    </a>",
"    ]. Among patients being treated with statins, non-HDL cholesterol appears to be more associated with risk than apo B or LDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, an analysis from the Health Professionals Follow-up Study found that apo B was a somewhat stronger predictor of CHD risk than non-HDL cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the above findings suggest a potential role of apolipoproteins for CHD risk stratification. However, assay methods need to be standardized and threshold and target values for diagnosis must be established before apo A-I and apo B are used routinely in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationships described above can be summarized by the data from the ARIC study, which followed 12,339 patients, ages 45 to 64, for 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal value for LDL cholesterol in both men and women is &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.58",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      a one standard deviation (38.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      LDL increase above the mean of 118",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.50",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      was associated with an age adjusted relative risk for CHD of 1.42 for men and 1.37 for women.",
"     </li>",
"     <li>",
"      A one standard deviation increase in HDL cholesterol (15.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.40",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      above the mean of 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.18",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in men and 51",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.51",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in women was associated with an adjusted relative risk of 0.64 and 0.69, respectively.",
"     </li>",
"     <li>",
"      A one standard deviation increase in Lp(a) (10",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      above the mean of 8.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in men and 11",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in women was associated with a relative risk of 1.15 and 1.17, respectively.",
"     </li>",
"     <li>",
"      Triglycerides were an independent predictor of CHD only in women in whom a one standard deviation increase (62",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      above the mean of 115",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      was associated with a relative risk of 1.31.",
"     </li>",
"     <li>",
"      Prediction of CHD was not enhanced by HDL subfractions.",
"     </li>",
"     <li>",
"      When used in combination with blood pressure, smoking, and diabetes, LDL cholesterol, HDL cholesterol, Lp(a) and triglycerides (in women) provided a relative risk for CHD (calculated as CHD rate among those in the two deciles of highest risk divided by the CHD rate in the lowest four deciles of risk) of 4.9 and 13.5 in men and women, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the AMORIS study described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/42\">",
"     42",
"    </a>",
"    ], apo A-1 and apo B did not contribute to risk prediction in ARIC. The explanation for these disparate findings is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LIPOPROTEIN MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard serum lipid profile consists of total cholesterol, triglycerides, and HDL-cholesterol. Lipoprotein analysis should be performed after 9 to 12 hours of fasting to minimize the influence of postprandial hyperlipidemia. Either a plasma or serum specimen can be used; the serum cholesterol is approximately 3 percent lower than the plasma value.",
"   </p>",
"   <p>",
"    Serum total and HDL-cholesterol can be measured in fasting or nonfasting individuals; there are only small clinically insignificant differences in these values when measured in the fasting or nonfasting state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/54\">",
"     54",
"    </a>",
"    ]. The total cholesterol can vary by 4 to 11 percent within an individual due to multiple factors including stress, minor illness, and posture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/55\">",
"     55",
"    </a>",
"    ]. Values may also vary between different laboratories, with data suggesting that a single measurement of serum cholesterol can vary as much as 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Thus, more than one measurement of total cholesterol should be obtained when treatment considerations demand a precise determination. Measurement of serum HDL-C and triglycerides may demonstrate even greater variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/57\">",
"     57",
"    </a>",
"    ]. This is discussed in greater depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31222?source=see_link\">",
"     \"Measurement of serum lipids and lipoproteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several models have been formulated to identify patients at risk for CHD. ATP III outlined five major steps in risk stratification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtain a fasting lipid profile",
"     </li>",
"     <li>",
"      Identify the presence of CHD equivalents",
"     </li>",
"     <li>",
"      Identify the presence of other major CHD risk factors",
"     </li>",
"     <li>",
"      If two or more risk factors other than LDL (as defined in step 3) are present in a patient without CHD or a CHD equivalent (as defined in step 2), the 10-year risk of CHD is assessed using the ATP III modification of the Framingham risk tables (",
"      <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"mobipreview.htm?30/1/30751\">",
"       table 5A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Determine the risk category that establishes the LDL goal, when to initiate therapeutic lifestyle changes, and when to consider drug therapy (",
"      <a class=\"graphic graphic_table graphicRef82504 \" href=\"mobipreview.htm?11/4/11340\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other methods of risk assessment include use of the total",
"    <span class=\"nowrap\">",
"     cholesterol/HDL-cholesterol",
"    </span>",
"    ratio, measurement of the non-HDL cholesterol concentration, apolipoprotein B, and LDL particle concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link&amp;anchor=H2#H2\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\", section on 'Identification of patients at risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFICACY OF CHOLESTEROL LOWERING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective therapies, including lifestyle modification and pharmacologic therapies, exist for lowering serum lipids, and there are data showing that some of these therapies decrease the risk of cardiovascular disease when implemented or administered for primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     National Cholesterol Education Program guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;NCEP III (Adult Treatment Panel [ATP] III) screening guidelines for lipid abnormalities published in 2001 recommended that screening be performed at least once every five years for all persons age 20 and over [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/22\">",
"     22",
"    </a>",
"    ]. In a change from previous guidelines, a fasting lipid profile is recommended for screening, although if the testing opportunity is nonfasting, the total and HDL-cholesterol should be measured. In the latter circumstance, a total cholesterol &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or HDL cholesterol &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.03",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    suggests the need for a follow-up fasting lipid profile.",
"   </p>",
"   <p>",
"    Individuals without known CHD who have a desirable serum LDL cholesterol concentration (&lt;160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or &lt;3.4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    for 0 to one risk factor and &lt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for two or more risk factors) can be rescreened in five years. Patients with borderline-high cholesterol and less than two risk factors should be rescreened within one to two years (",
"    <a class=\"graphic graphic_table graphicRef70489 \" href=\"mobipreview.htm?31/39/32379\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The desirable LDL cholesterol level for those with CHD or CHD equivalent is &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&lt;2.6",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    CHD equivalents include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic carotid artery disease",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Abdominal aortic aneurysm",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     United States Preventive Services Task Force",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPSTF guidelines issued in 2008 strongly recommend that clinicians routinely screen men ages 35 years and older for lipid disorders (grade A recommendation) (",
"    <a class=\"graphic graphic_table graphicRef75920 \" href=\"mobipreview.htm?32/29/33243\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/58\">",
"     58",
"    </a>",
"    ]. The USPSTF also recommends screening younger men (over the age of 20) for lipid disorders if they have other risk factors for CHD (B recommendation). They make no recommendation for or against routine screening in younger adults who do not have risk factors for CHD (C recommendation).",
"   </p>",
"   <p>",
"    The USPSTF recommends screening women for lipid disorders only if they have other risk factors for CHD. They make an A recommendation for this in women ages 45 and older with CHD risk factors and a B recommendation in women between 20 and 45 with CHD risk factors. This was based in part on a concern that there was limited evidence for benefit from treating dyslipidemias in asymptomatic women. However, since the 2008 USPSTF report, an additional large randomized trial has demonstrated similar relative benefits with statin treatment in asymptomatic men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/59\">",
"     59",
"    </a>",
"    ]. Prior USPSTF guidelines recommended screening all women starting at age 45, and we continue to feel that such screening is appropriate even in women without known CHD risk factors.",
"   </p>",
"   <p>",
"    The USPSTF states that the preferred screening tests are measurement of total cholesterol and HDL-cholesterol and that evidence is insufficient to recommend for or against triglyceride measurement as part of routine screening.",
"   </p>",
"   <p>",
"    The Task Force concluded that the optimal interval for screening is uncertain; reasonable options include every five years, or shorter for people who have lipid levels that are close to warranting therapy, or longer for low risk people with repeatedly low or normal values. An age to stop screening was not established; screening may be appropriate in older people who have never been screened, but repeated screening is less important in older people because lipid levels are less likely to increase after age 65. The USPSTF clinical practice guideline for screening adults for lipid disorders, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other groups have issued the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Canadian Working Group on Hypercholesterolemia and Other Dyslipidemias recommends routine screening of men over age 40 and women over age 50 in addition to screening people with risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Academy of Family Physicians (AAFP) recommends screening for lipid disorders with either a fasting lipid profile or nonfasting total cholesterol and HDL cholesterol in males age 35 and older, and females age 45 and older [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American College of Physicians (ACP) in 1996 recommended that a screening serum cholesterol was appropriate but not mandatory for asymptomatic men ages 35 to 65 and women ages 45 to 65 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/62\">",
"       62",
"      </a>",
"      ]. Screening was not recommended for younger individuals unless they had multiple cardiovascular risk factors or were suspected of having a familial lipoprotein disorder. The ACP recommended against screening individuals over the age of 75, but found insufficient evidence to recommend for or against screening for those between the ages of 65 and 75.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Predictive value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of the NCEP II model for predicting CHD death was validated for primary prevention against the Lipid Research Clinic Prevalence and Follow-up Studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/63\">",
"     63",
"    </a>",
"    ]. The screening guidelines had a sensitivity of 45 percent, specificity of 86 percent, and a positive predictive value (area under the curve) of 0.74. (A perfect screening test has an area of 1.00; a nondiscriminating test an area of 0.50.) The guidelines were not significantly better predictors of coronary mortality than the ratio of total cholesterol to HDL-cholesterol. The accuracy of the ATP III guidelines has not yet been determined.",
"   </p>",
"   <p>",
"    The CHD Prevention model developed from the Framingham Heart Study is a better predictor than other guidelines: area 0.85, sensitivity 70 percent, and specificity 82 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33241/abstract/4,64\">",
"     4,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin therapy is effective for primary prevention of CHD in elderly hypercholesterolemic patients. It therefore seems reasonable to consider screening and treating elderly patients with a reasonable life expectancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10760?source=see_link\">",
"     \"Treatment of dyslipidemia in the older adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Exclusion of secondary causes of lipid abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with hypercholesterolemia who have a fasting lipoprotein analysis, a blood sample should also be sent for measurement of the concentrations of glucose, creatinine, liver enzymes, and uric acid, and for assessment of thyroid status. The aim is to detect important secondary causes of abnormal lipid metabolism, such as diabetes mellitus, renal failure, and hypothyroidism. Heavy proteinuria should also be excluded, since the nephrotic syndrome can induced pronounced hypercholesterolemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=see_link\">",
"     \"Secondary causes of dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/48/11011?source=see_link\">",
"       \"Patient information: High cholesterol (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/28/20930?source=see_link\">",
"       \"Patient information: High triglycerides (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/1\">",
"      Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000; 85:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Coronary heart disease mortality trends among whites and blacks--Appalachia and United States, 1980-1993. MMWR Morb Mortal Wkly Rep 1998; 47:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/3\">",
"      Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/4\">",
"      Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/5\">",
"      Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 1992; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     The Expert Panel. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 93-3095, US Government Printing Office; Washington, DC 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/7\">",
"      Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb Mortal Wkly Rep 2011; 60:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/9\">",
"      Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3&middot;0 million participants. Lancet 2011; 377:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/10\">",
"      Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/11\">",
"      Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/12\">",
"      Stamler J, Daviglus ML, Garside DB, et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/13\">",
"      Pletcher MJ, Bibbins-Domingo K, Liu K, et al. Nonoptimal lipids commonly present in young adults and coronary calcium later in life: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann Intern Med 2010; 153:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/14\">",
"      Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/15\">",
"      Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/16\">",
"      Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988; 148:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/17\">",
"      Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/18\">",
"      Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/19\">",
"      LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/20\">",
"      Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/21\">",
"      Otvos JD, Cromwell W, Shalaurova I, Schaefer EJ. LDL particles, but not LDL cholesterol, are highly elevated in the metabolic syndrome: results from the Framingham Offspring Study. Circulation 2003; 108 (Suppl IV):740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/22\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/23\">",
"      Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/24\">",
"      Romm PA, Green CE, Reagan K, Rackley CE. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am J Cardiol 1991; 67:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/25\">",
"      Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 1983; 106:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/26\">",
"      Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/27\">",
"      Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/28\">",
"      Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/29\">",
"      Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/30\">",
"      Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/31\">",
"      Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/32\">",
"      Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 2000; 160:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/33\">",
"      Cobbaert C, Jukema JW, Zwinderman AH, et al. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol 1997; 30:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/34\">",
"      Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/35\">",
"      Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2002; 160:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/36\">",
"      Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/37\">",
"      Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002; 22:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/38\">",
"      Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/39\">",
"      El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 49:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/40\">",
"      Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005; 26:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/41\">",
"      Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Qu&eacute;bec cardiovascular study. Circulation 1996; 94:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/42\">",
"      Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/43\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/44\">",
"      Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/45\">",
"      Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/46\">",
"      Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Qu&eacute;bec Cardiovascular Study. Circulation 1997; 95:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/47\">",
"      Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/48\">",
"      Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/49\">",
"      Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/50\">",
"      Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/51\">",
"      Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is... Circulation 2005; 112:3366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/52\">",
"      Srinivasan SR, Berenson GS. Apolipoproteins B and A-I as predictors of risk of coronary artery disease. Lancet 2001; 358:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/53\">",
"      Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 2005; 112:3368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/54\">",
"      Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/55\">",
"      Cooper GR, Myers GL, Smith SJ, Schlant RC. Blood lipid measurements. Variations and practical utility. JAMA 1992; 267:1652.",
"     </a>",
"    </li>",
"    <li>",
"     United States Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed, Williams and Wilkins, Baltimore 1996. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/57\">",
"      Bachorik PS, Cloey TA, Finney CA, et al. Lipoprotein-cholesterol analysis during screening: accuracy and reliability. Ann Intern Med 1991; 114:741.",
"     </a>",
"    </li>",
"    <li>",
"     www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm (Accessed on January 18, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/59\">",
"      Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/60\">",
"      Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169:921.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Family Physicians. Available at: www.aafp.org/PreBuilt/PHErev54.pdf (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/62\">",
"      Haq IU, Jackson PR, Ramsay LE. American College of Physicians guidelines on cholesterol screening. Ann Intern Med 1996; 125:1010; author reply 1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/63\">",
"      Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33241/abstract/64\">",
"      Grover SA, Abrahamowicz M, Joseph L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity. JAMA 1992; 267:816.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4553 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33241=[""].join("\n");
var outline_f32_29_33241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSOCIATION BETWEEN DYSLIPIDEMIA AND CORONARY RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Low density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Total cholesterol to HDL ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Triglycerides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lipoprotein(a)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-HDL-cholesterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LDL subclasses and LDL particle concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Apolipoproteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LIPOPROTEIN MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFICACY OF CHOLESTEROL LOWERING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      National Cholesterol Education Program guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      United States Preventive Services Task Force",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Predictive value",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Exclusion of secondary causes of lipid abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4553|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25086\" title=\"figure 1\">",
"      Number of risk factors and CVD risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/40/16014\" title=\"figure 2\">",
"      Lipids and premature CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/19/317\" title=\"figure 3A\">",
"      Increasing plasma cholesterol and coronary risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/19/34109\" title=\"figure 3B\">",
"      Plasma cholesterol and cardiovascular mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/47/17142\" title=\"figure 4\">",
"      Antioxidants and atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/12/31950\" title=\"figure 5\">",
"      Value of lipid markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/9/6302\" title=\"figure 6\">",
"      TG LDL HDL and coronary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/63/19453\" title=\"table 1\">",
"      Normal values for lipid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/53/1883\" title=\"table 2\">",
"      Oxidized LDL in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/39/32379\" title=\"table 3\">",
"      ATPIII classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/2/35\" title=\"table 4\">",
"      HDL-C and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/61/10206\" title=\"table 5A\">",
"      Framingham ATPIII score men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/17/8478\" title=\"table 5B\">",
"      Framingham ATPIII score women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/4/11340\" title=\"table 6\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/29/33243\" title=\"table 7\">",
"      USPSTF recommendation grade",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31222?source=related_link\">",
"      Measurement of serum lipids and lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/28/20930?source=related_link\">",
"      Patient information: High triglycerides (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10760?source=related_link\">",
"      Treatment of dyslipidemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_29_33242="Initial assessment and management of acute stroke";
var content_f32_29_33242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial assessment and management of acute stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33242/contributors\">",
"     Jamary Oliveira-Filho, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33242/contributors\">",
"     Walter J Koroshetz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33242/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33242/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/29/33242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/29/33242/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/29/33242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subacute and long-term assessment and management of patients who have suffered a stroke includes physical therapy and testing to determine the precise etiology of the event so as to prevent recurrence. The acute management differs. Immediate goals include minimizing brain injury, treating medical complications, and moving toward uncovering the pathophysiologic basis of the patient's symptoms.",
"   </p>",
"   <p>",
"    Patient assessment and management during the acute phase (first few hours) of an ischemic stroke will be reviewed here. Use of thrombolytic therapy, treatment of patients not eligible for thrombolytic therapy, the clinical diagnosis of various types of stroke, and the subacute and long-term assessment of patients who have had a stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden loss of focal brain function is the core feature of the onset of ischemic stroke. However, patients with conditions other than brain ischemia may present in a similar fashion (",
"    <a class=\"graphic graphic_table graphicRef69869 \" href=\"mobipreview.htm?26/51/27451\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients suffering a stroke may present with other serious medical conditions. Thus, the initial evaluation requires a rapid but broad assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals in the initial phase include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ensuring medical stability, with particular attention to airway, breathing, and circulation",
"     </li>",
"     <li>",
"      Quickly reversing any conditions that are contributing to the patient's problem",
"     </li>",
"     <li>",
"      Determining if patients with acute ischemic stroke are candidates for thrombolytic therapy (",
"      <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Moving toward uncovering the pathophysiologic basis of the patient's neurologic symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66230911\">",
"    <span class=\"h2\">",
"     Airway, breathing and circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing vital signs and ensuring stabilization of airway, breathing, and circulation is the part of the initial evaluation of all patients with critical illness, including those with stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with increased intracranial pressure due to hemorrhage, vertebrobasilar ischemia, or bihemispheric ischemia can present with a decreased respiratory drive or muscular airway obstruction. Hypoventilation, with a resulting increase in carbon dioxide, may lead to cerebral vasodilation, which further elevates intracranial pressure.",
"   </p>",
"   <p>",
"    Intubation may be necessary to restore adequate ventilation and to protect the airway from aspiration; this is especially important in the presence of vomiting, which occurs commonly with increased intracranial pressure, vertebrobasilar ischemia, and intracranial hemorrhage. Patients with adequate ventilation should have the oxygen saturation monitored. Patients who are hypoxic should receive supplemental oxygen to maintain oxygen saturation &gt;94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. Supplemental oxygen should not routinely be given to nonhypoxic stroke victims [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the time of ischemic stroke symptom onset is critical because it is the main determinant of eligibility for treatment with intravenous thrombolysis (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"     table 2",
"    </a>",
"    ). For patients who are unable to provide a reliable onset time, it is defined as the time the patient was last awake and free of stroke symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The history and physical examination should be used to distinguish between other disorders in the differential diagnosis of brain ischemia (",
"    <a class=\"graphic graphic_table graphicRef69869 \" href=\"mobipreview.htm?26/51/27451\">",
"     table 1",
"    </a>",
"    ). As examples, seizures, syncope, migraine, hypoglycemia (see",
"    <a class=\"local\" href=\"#H100191313\">",
"     'Hypoglycemia'",
"    </a>",
"    below), or drug toxicity can mimic acute ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The most difficult cases involve patients with focal signs and altered level of consciousness. It is important to ask the patient or a relative whether the patient takes insulin or oral hypoglycemic agents, has a history of a seizure disorder or drug overdose or abuse, medications on admission, or recent trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36439?source=see_link\">",
"     \"Differential diagnosis of transient ischemic attack and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosing an intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) as soon as possible can be lifesaving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1\">",
"     1",
"    </a>",
"    ]. The history may be helpful in this regard. The presence of onset headache and vomiting favor the diagnosis of ICH or SAH compared with a thromboembolic stroke (",
"    <a class=\"graphic graphic_figure graphicRef60831 \" href=\"mobipreview.htm?0/5/88\">",
"     figure 1",
"    </a>",
"    ), while the abrupt onset of impaired cerebral function without focal symptoms favors the diagnosis of SAH. Even with these clues, diagnosing intracranial hemorrhage on clinical grounds is very imprecise, so early triage of the patient to CT or MRI scan is critical. However, it is important to assess and optimize vital physiologic function",
"    <strong>",
"     before",
"    </strong>",
"    sending the patient for an imaging study.",
"   </p>",
"   <p>",
"    The physical examination should include careful evaluation of the neck and retroorbital regions for vascular bruits, and palpation of pulses in the neck, arms, and legs to assess for their absence, asymmetry, or irregular rate. The heart should be auscultated for murmurs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The skin should be examined for signs of endocarditis, cholesterol emboli, purpura, or ecchymoses. The funduscopic examination may be helpful if there are cholesterol emboli or papilledema. The head should be examined for signs of trauma. A tongue laceration may occur with tongue biting during a seizure.",
"   </p>",
"   <p>",
"    The neck should be immobilized, if there is a report or suspicion of a fall, until evaluated radiographically for evidence of serious trauma. Examination of the extremities is important to detect deep vein thrombosis, which can cause systemic embolization in patients with a patent foramen ovale, and to look for evidence of systemic arterial emboli from other sources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95636670\">",
"    <span class=\"h2\">",
"     Neurologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Time is of the essence in the hyperacute evaluation of stroke patients; all tests should lead to a \"best guess\" of the stroke mechanism, which will eventually guide therapy. The history, physical examination, serum glucose, oxygen saturation, and a noncontrast CT scan are sufficient in most cases. Other tests are ordered on a patient-to-patient basis but should not be a reason to delay therapy.",
"   </p>",
"   <p>",
"    The two key questions to address are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are the patient's symptoms due to brain ischemia?",
"     </li>",
"     <li>",
"      What is the patient's risk of major permanent functional deficit from the ischemic insult?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The answer to each question is dependent upon a number of variables, the most important of which is the presence and nature of the vascular lesion underlying the clinical presentation. For patients presenting within the therapeutic window for thrombolysis (less than 4.5 hours from symptom onset), the history needs to be accurate but rapid; contraindications to thrombolytic treatment should also be assessed (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link&amp;anchor=H548320#H548320\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Patient selection and eligibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ischemia in different vascular territories presents with specific syndromes, some of which provide a clue to the underlying stroke pathophysiology (",
"    <a class=\"graphic graphic_table graphicRef75487 \" href=\"mobipreview.htm?27/15/27900\">",
"     table 3",
"    </a>",
"    ). The history should focus upon the time of symptom onset, the course of symptoms over time, possible embolic sources, items in the differential diagnosis, and concomitant diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neurologic examination should attempt to confirm the findings from the history and provide a quantifiable examination for further assessment over time. Many scales are available that provide a structured, quantifiable neurologic examination. One of the most widely used and validated scales is the NIH Stroke Scale (NIHSS), composed of 11 items adding up to a total score of 0 to 42 (",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three most predictive examination findings for the diagnosis of acute stroke are facial paresis, arm",
"    <span class=\"nowrap\">",
"     drift/weakness,",
"    </span>",
"    and abnormal speech (a combination of dysarthria and language items derived from the NIHSS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The NIHSS score on admission has been correlated to stroke outcome (",
"    <a class=\"graphic graphic_table graphicRef81859 \" href=\"mobipreview.htm?21/2/21548\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and its use is recommended for all patients with suspected stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95644450\">",
"    <span class=\"h2\">",
"     Immediate laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent brain imaging with CT or MRI is mandatory in all patients with sudden neurologic deterioration or acute stroke. (See",
"    <a class=\"local\" href=\"#H95646379\">",
"     'Neuroimaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All patients with suspected stroke should have the following studies emergently as part of the acute stroke evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Noncontrast brain CT or brain MRI",
"     </li>",
"     <li>",
"      Serum glucose",
"     </li>",
"     <li>",
"      Oxygen saturation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other immediate tests for the evaluation of ischemic and hemorrhagic stroke include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Complete blood count including platelets",
"     </li>",
"     <li>",
"      Cardiac enzymes and troponin",
"     </li>",
"     <li>",
"      Serum electrolytes, urea nitrogen, creatinine",
"     </li>",
"     <li>",
"      Prothrombin time and international normalized ratio (INR)",
"     </li>",
"     <li>",
"      Activated partial thromboplastin time",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, fibrinolytic therapy for acute ischemic stroke (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Acute therapy'",
"    </a>",
"    below) should not be delayed while awaiting the results of hematologic studies unless the patient has received anticoagulants or there is suspicion of a bleeding abnormality or thrombocytopenia.",
"   </p>",
"   <p>",
"    The following laboratory studies are appropriate in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Toxicology screen",
"     </li>",
"     <li>",
"      Blood alcohol level",
"     </li>",
"     <li>",
"      Pregnancy test in women of child-bearing potential",
"     </li>",
"     <li>",
"      Arterial blood gas if hypoxia is suspected",
"     </li>",
"     <li>",
"      Chest radiograph if lung disease is suspected",
"     </li>",
"     <li>",
"      Lumbar puncture if subarachnoid hemorrhage is suspected and head CT scan is negative for blood",
"     </li>",
"     <li>",
"      Electroencephalogram if seizures are suspected",
"     </li>",
"     <li>",
"      Thrombin time and or ecarin clotting time if known or suspected that the patient is taking direct thrombin inhibitor or direct factor Xa inhibitor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these tests, we suggest obtaining a finger stick for faster glucose measurement if the patient is diabetic, taking insulin or oral hypoglycemic agents, or if there is clinical suspicion for hypoglycemia. Chest radiography, urinalysis and blood cultures are indicated if fever is present. We also suggest blood for type and cross match in case fresh frozen plasma is needed to reverse a coagulopathy if ICH is present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to limit medication dosage errors, particularly with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , an accurate body weight should be obtained upon admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95646379\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the evaluation of the acute stroke patient, imaging studies are necessary to exclude hemorrhage as a cause of the deficit, and they are useful to assess the degree of brain injury and to identify the vascular lesion responsible for the ischemic deficit. Some advanced CT and MRI technologies are able to distinguish between brain tissue that is irreversibly infarcted and that which is potentially salvageable, thereby allowing better selection of patients who are likely to benefit from therapy. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95646729\">",
"    <span class=\"h3\">",
"     Cardiac studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiography (ECG) is important for detecting signs of concomitant acute cardiac ischemia. This test is particularly important in the setting of stroke, as patients with ischemic stroke frequently harbor coronary artery disease but may not be able to report chest pain.",
"   </p>",
"   <p>",
"    Stroke alone can be associated with ECG changes. The sympathetic response to stroke can lead to demand-induced myocardial ischemia. In large strokes, especially subarachnoid hemorrhage, there are centrally mediated changes in the ECG.",
"   </p>",
"   <p>",
"    The ECG and cardiac monitoring are important for the detection of chronic arrhythmias that predispose to embolic events (eg, atrial fibrillation) and for detecting indirect evidence of",
"    <span class=\"nowrap\">",
"     atrial/ventricular",
"    </span>",
"    enlargement that may predispose to thrombus formation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac monitoring should be used for at least the first 24 hours after the onset of ischemic stroke to look for atrial fibrillation or other potentially serious cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. The utility of this approach is illustrated by the findings of a systematic review of five prospective studies that included a total of 588 hospitalized patients with ischemic stroke who had Holter monitoring for 21 to 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/10\">",
"     10",
"    </a>",
"    ]. Monitoring detected new atrial fibrillation or atrial flutter in 4.6 percent of these patients (95% CI 0-12.7 percent).",
"   </p>",
"   <p>",
"    Transthoracic and transesophageal echocardiography adequately detect cardiogenic and aortic sources for cerebral embolism (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    ). However, their use can be postponed until after the acute treatment phase, when the patient is in a more stable clinical condition. Exceptions include patients with a moderate or high suspicion of endocarditis, where echocardiography may provide confirmation of the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic approach to infective endocarditis\", section on 'Echocardiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of the evaluation of stroke\", section on 'Cardiac evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100189574\">",
"    <span class=\"h1\">",
"     STROKE MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to stabilization of airway, breathing, and circulation, and rapid neurologic evaluation discussed above, early key management issues that often arise in acute stroke include blood pressure control (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Blood pressure management'",
"    </a>",
"    below), swallowing assessment (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Swallowing assessment'",
"    </a>",
"    below), treatment of abnormal blood glucose levels (see",
"    <a class=\"local\" href=\"#H100191313\">",
"     'Hypoglycemia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H100191613\">",
"     'Hyperglycemia'",
"    </a>",
"    below), and treatment of fever and infection (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Fever'",
"    </a>",
"    below). Care in a dedicated stroke unite (see",
"    <a class=\"local\" href=\"#H68922375\">",
"     'Stroke unit care'",
"    </a>",
"    below) is associated with better outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100191313\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia can cause focal neurologic deficits mimicking stroke, and severe hypoglycemia alone can cause neuronal injury. It is important to check the blood sugar and rapidly correct low serum glucose (&lt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 3.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at the first opportunity. Normoglycemia is the desired goal while avoiding marked elevation of serum glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100191613\">",
"    <span class=\"h2\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia, generally defined as a blood glucose level &gt;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;7.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    is common in patients with acute stroke and is associated with poor functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. In a series of 59 patients with acute ischemic stroke, admission hyperglycemia was present in 32 percent of patients without diabetes and 81 percent of patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/16\">",
"     16",
"    </a>",
"    ]. Stress hyperglycemia may be the most common cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/13\">",
"     13",
"    </a>",
"    ], although newly diagnosed diabetes is also important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperglycemia may augment brain injury by several mechanisms including increased tissue acidosis from anaerobic metabolism, free radical generation, and increased blood brain barrier permeability. Several lines of evidence point to the deleterious effects of elevated glucose in acute stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperglycemia worsens ischemic damage in animal models of stroke",
"     </li>",
"     <li>",
"      Glucose reduction decreases ischemic damage in experimental models",
"     </li>",
"     <li>",
"      Acute hyperglycemia is associated with reduced salvage of penumbral tissue and greater final infarct size by neuroimaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hyperglycemia is associated with reduced benefit from recanalization with thrombolytic therapy and higher odds for symptomatic intracerebral hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of these observations, it is reasonable to treat severe hyperglycemia in the setting of acute stroke. The American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association guidelines for acute ischemic stroke recommend treatment for hyperglycemia to achieve serum glucose concentrations in the range of 140 to 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 to 10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. The European Stroke Initiative guidelines recommend treatment for glucose &gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ongoing NINDS-funded multicenter randomized trial (SHINE) is evaluating whether tight control of glucose with intravenous insulin improves outcome in patients with acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, the available evidence suggests that it does not. A 2011 systematic review identified seven controlled trials involving nearly 1300 adults with acute ischemic stroke who were randomly assigned to either intensively monitored insulin infusion therapy or to usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/23\">",
"     23",
"    </a>",
"    ]. There was no difference between the treatment and control groups for the combined outcome of death or disability and dependence, and no difference between groups for the outcome of final neurologic deficit. In addition, the intervention group had a higher rate of symptomatic hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Swallowing assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia is common after stroke and is a major risk factor for developing aspiration pneumonia. It is important to assess swallowing function prior to administering oral medications or food. Thus, prevention of aspiration in patients with acute stroke includes initial nulla per os (NPO) status until swallowing function is evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H11#H11\">",
"     \"Medical complications of stroke\", section on 'Dysphagia and aspiration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Head and body position",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the acute phase of stroke, the position of the patient and the head of bed should be individualized with respect to the risk of elevated intracranial pressure and aspiration, and the presence of comorbid cardiopulmonary disease. However, available data are limited, and no randomized trials have addressed these issues.",
"   </p>",
"   <p>",
"    A number of reports suggest that cerebral perfusion pressure or intracranial large artery flow velocity is maximal when patients are in the horizontal position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As an example, in a study involving 20 patients with moderately severe ischemic stroke in the middle cerebral artery (MCA) territory, mean flow velocity in the MCA measured by transcranial Doppler increased by an average of 20 percent when the head-of-bed elevation decreased from 30 to 0 degrees, and by an average of 12 percent when head-of-bed elevation decreased from 30 to 15 degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, a supine position is preferred for nonhypoxic patients with acute ischemic stroke who are able to tolerate lying flat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, some patients with acute ischemic stroke may develop increased ischemic symptoms upon standing, sitting, or elevating the head of the bed, due to reduction in flow through stenotic vessels or collateral pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, elevated intracranial pressure may be exacerbated with flat head-of-bed positioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/24\">",
"     24",
"    </a>",
"    ], although significant aggravation of elevated intracranial pressure is unlikely in the first 24 hours after ischemic stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Thus, patients with intracerebral hemorrhage, large ischemic infarction, or another large space-occupying lesion should be maintained at 30 degrees in bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1\">",
"     1",
"    </a>",
"    ]. This issue is discussed separately for patients with intracerebral hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link&amp;anchor=H16#H16\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Intracranial pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, flat head positioning may not be tolerated well in some patients with cardiac and pulmonary disease (eg, heart failure). Such patients may need head elevation to improve oxygenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, the head of bed position should be individualized for each patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend keeping the head in neutral alignment with the body and elevating the head of the bed to 30 degrees for all patients in the acute phase of stroke who are at risk for any of the following problems:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Elevated intracranial pressure (eg, with large ischemic stroke, intracerebral hemorrhage, space-occupying lesion, or other cause of elevated intracranial pressure)",
"     </li>",
"     <li>",
"      Aspiration (eg, those with dysphagia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diminished consciousness)",
"     </li>",
"     <li>",
"      Cardiopulmonary decompensation or oxygen desaturation (eg, those with chronic cardiac and pulmonary disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest keeping the head of bed flat (0 to 15 degree head-of-bed position) for patients in the acute phase of stroke who are not at risk for elevated intracranial pressure, aspiration, or worsening cardiopulmonary status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Keeping the patient flat is a temporary measure that should be discontinued in most patients after 24 to 48 hours. National guidelines favor early mobilization because it lessens the likelihood of major complications such as pneumonia, deep vein thrombosis, pulmonary embolism, and pressure sores after stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. Exceptions may include those who exhibit neurologic deterioration upon assuming more upright postures. For this reason, close observation is recommended when patient position is altered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ], as during the transition from lying to sitting and standing. In addition, there is a potential increased risk of aspiration if a flat position is maintained for a prolonged period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever has special significance in patients presenting with acute neurologic deterioration. Both problems may occur in patients with a primary central nervous system infection such as meningitis, subdural empyema, brain abscess, and infective endocarditis. These conditions need to be excluded as the etiology of fever. In addition, common etiologies of fever including aspiration pneumonia and urinary tract infection should also be excluded.",
"   </p>",
"   <p>",
"    Fever may contribute to brain injury in patients with an acute stroke. This concept has been demonstrated in animal models in which ischemic injury is increased in the presence of elevated temperature. Hyperthermia may act via several mechanisms to worsen cerebral ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enhanced release of neurotransmitters",
"     </li>",
"     <li>",
"      Exaggerated oxygen radical production",
"     </li>",
"     <li>",
"      More extensive blood-brain barrier breakdown",
"     </li>",
"     <li>",
"      Increased numbers of potentially damaging ischemic depolarizations in the focal ischemic penumbra",
"     </li>",
"     <li>",
"      Impaired recovery of energy metabolism and enhanced inhibition of protein kinases",
"     </li>",
"     <li>",
"      Worsening of cytoskeletal proteolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever is associated with unfavorable outcomes in human studies of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. One meta-analysis analyzed fever and outcome in patients with neurologic injury, including hemorrhagic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/36\">",
"     36",
"    </a>",
"    ]. Fever was significantly associated with increased mortality rates, greater disability, more dependence, worse functional outcome, greater severity, and longer intensive care unit and hospital stays. These results were consistent for overall pooled data and for subgroups limited to studies of patients with hemorrhagic, ischemic, or all stroke types. A subsequent meta-analysis found that fever within 24 hours of hospital admission in patients with ischemic stroke was associated with a two-fold increase in the odds of mortality at one month after stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The source of fever should be investigated and treated, and antipyretics should be used to lower temperature in febrile patients with acute stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. We suggest maintaining normothermia for at least the first several days after an acute stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the clinical utility of this approach has not been established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PAIS trial evaluated 1400 adults no later than 12 hours after symptom onset of acute ischemic stroke intracerebral hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/40\">",
"       40",
"      </a>",
"      ]. Included patients had a body temperature of 36&ordm;C to 39&ordm;C. Compared with placebo, paracetamol (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ) 1 g six times daily for three days did not improve outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/40\">",
"       40",
"      </a>",
"      ]. However, a post-hoc subgroup analysis of 661 patients with a baseline body temperature of 37&ordm;C to 39&ordm;C suggested benefit for paracetamol.",
"     </li>",
"     <li>",
"      In a systematic review and meta-analysis of five small randomized controlled trials with a total of 293 patients, there was no benefit for pharmacologic temperature reduction for acute stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/41\">",
"       41",
"      </a>",
"      ]. All the trials enrolled patients within 24 hours of stroke onset, and the duration of treatment ranged from 24 hours to five days. With addition of results from the PAIS trial, the updated meta-analysis found no difference between active treatment and control for a favorable outcome (odds ratio 1.1, 95% CI 0.9-1.3) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger trials are needed to determine if pharmacologic temperature reduction improves outcome from acute stroke, particularly for patients with temperature of &ge;37&ordm;C, though it seems unlikely that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    will be effective by itself.",
"   </p>",
"   <p>",
"    Induced hypothermia is not currently recommended for patients with ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ], outside of clinical trials. An NINDS-funded randomized trial",
"    <span class=\"nowrap\">",
"     (ICTuS2/3)",
"    </span>",
"    evaluating the combination of hypothermia and thrombolysis versus thrombolysis alone is currently underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68922375\">",
"    <span class=\"h2\">",
"     Stroke unit care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mounting evidence suggests that patients with acute stroke have better outcomes when admitted to a hospital unit that is specialized for the care of patients with all types of acute stroke, including ischemic, intracerebral hemorrhage, and subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The precise components of an acute stroke unit vary between centers and countries, but generally include a hospital ward with dedicated telemetry beds that is continuously staffed by a team of physicians, nurses and other personnel who specialize in stroke care, emphasizing expertise in vascular neurology and neurosurgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Additional components include prompt availability of neuroimaging (eg, CT, MRI, various types of angiography, ultrasound, transcranial Doppler) and cardiac imaging. Implementation of stroke protocols and disease-performance measures may contribute to improved outcomes and decreased risk of stroke-related complications, as shown in some reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current national guidelines support stroke unit care, when available, for patients with suspected acute stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2,50\">",
"     2,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BLOOD PRESSURE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of blood pressure in acute stroke is reviewed here. Chronic management of blood pressure after stroke is discussed separately, as is the management of blood pressure in patients who are being treated with thrombolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17305?source=see_link\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link&amp;anchor=H551003#H551003\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Management of blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with ischemic stroke, the perfusion pressure distal to the obstructed vessel is low, and the distal vessels are dilated. Blood flow in these dilated vessels is thought to be dependent upon the systemic blood pressure.",
"   </p>",
"   <p>",
"    The arterial blood pressure is usually elevated in patients with an acute stroke. This may be due to chronic hypertension, an acute sympathetic response, or to other stroke-mediated mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/51\">",
"     51",
"    </a>",
"    ]. In many cases, however, the acutely elevated blood pressure is necessary to maintain brain perfusion in borderline ischemic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/52\">",
"     52",
"    </a>",
"    ]. A neuroimaging study with CT or MRI is critical to help guide blood pressure therapy in stroke patients.",
"   </p>",
"   <p>",
"    The observation that the blood pressure frequently rises spontaneously following cerebral ischemia is consistent with this protective hypothesis, although a stress response to the acute event and to hospitalization may also contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/53\">",
"     53",
"    </a>",
"    ]. The hypertensive effect is transient, as blood pressure falls by as much as",
"    <span class=\"nowrap\">",
"     20/10",
"    </span>",
"    mmHg within 10 days.",
"   </p>",
"   <p>",
"    An analysis from the International Stroke Trial of 17,398 patients with an ischemic stroke noted a U-shaped relationship between baseline systolic blood pressure and outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/54\">",
"     54",
"    </a>",
"    ]. Elevated systolic blood pressure was associated with an increased risk of recurrent ischemic stroke (50 percent greater risk of recurrence with a systolic blood pressure of &gt;200 mmHg versus 130 mmHg), while low blood pressure (particularly &lt;120 mmHg) was associated with an excess number of deaths from coronary heart disease.",
"   </p>",
"   <p>",
"    A subsequent analysis of 1004 patients with acute ischemic stroke from Okinawa also found a U-shaped relationship between admission blood pressure and death within 30 days after stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/55\">",
"     55",
"    </a>",
"    ]. The U-shaped relationship was shifted toward higher pressure in patients who had previous hypertension compared with those who did not have previous hypertension. This finding mirrors the shift seen in cerebral autoregulation that occurs in longstanding hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term benefit from antihypertensive therapy does not mean that a reduction in blood pressure will be beneficial during initial management of an acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/57\">",
"     57",
"    </a>",
"    ]. Lowering the systemic blood pressure in patients with acute ischemic stroke has been associated with clinical deterioration. Observational studies from several different groups have found an adverse effect of reducing blood pressure in the first 24 hours after stroke onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Odds ratios [OR] of poor outcome were similar in the first two studies: OR 1.9 per 10 percent systolic blood pressure reduction (95% CI, 1.02-3.52) in a Brazilian study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/58\">",
"     58",
"    </a>",
"    ] and OR 3.8 for a greater than 25 percent diastolic blood pressure reduction (95% CI, 1.2-12.1) in an Austrian study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/59\">",
"     59",
"    </a>",
"    ]. In a Spanish study, a fall in systolic blood pressure &gt;20 mmHg in the first day was the most important variable associated with neurologic deterioration and poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/60\">",
"     60",
"    </a>",
"    ]. Considered together, these data support current blood pressure recommendations in acute ischemic stroke outlined below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Blood pressure goals ischemic stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Occasional patients even benefit from pharmacologic increases in blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/61\">",
"     61",
"    </a>",
"    ]. In a number of small studies, a subset of patients were treated with the pressor agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , and a systolic blood pressure threshold was identified below which ischemic deficits worsened and above which deficits improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. A separate group found improved aphasic deficits as blood pressure was increased pharmacologically, concomitant with improved perfusion on MR perfusion study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/64\">",
"     64",
"    </a>",
"    ]. Others have treated a small number of patients with norepinephrine to improve cerebral perfusion and concluded that the technique is safe and feasible, even in those patients who also received intravenous thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, severe increases in blood pressure can cause hypertensive encephalopathy, a condition that can mimic stroke. In this case, lowering the blood pressure is the indicated treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized controlled trials have not found a deleterious effect of blood pressure treatment in patients with stroke, but the available trials enrolled patients as long as 30 to 48 hours after stroke onset, and are therefore less informative regarding the impact of blood pressure treatment in the first hours of ischemic stroke.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SCAST trial, over 2000 adults with acute ischemic or hemorrhagic stroke (85 and 14 percent respectively) and a systolic blood pressure &ge;140 mmHG were randomly assigned to either antihypertensive therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      or to placebo within 30 hours (mean 18 hours) of symptom onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/66\">",
"       66",
"      </a>",
"      ]. Treatment continued for seven days. At six months, there was no significant difference in the composite outcome of vascular death, myocardial infarction or stroke between the candesartan and placebo groups (12 versus 11 percent, adjusted hazard ratio [HR] 1.09, 95% CI 0.84-1.41), and no significant difference in poor functional outcome (death or dependency) for candesartan and placebo (35 versus 33 percent, adjusted HR 1.17, 95% CI 1.00-1.38). The authors pointed out that treatment with candesartan was associated with a small but statistically nonsignificant increased risk for all the primary and secondary endpoints in the trial.",
"     </li>",
"     <li>",
"      The CHHIPS trial enrolled 179 adults with acute cerebral infarction or cerebral hemorrhage (approximately 14 percent) and an admission systolic blood pressure (SBP) &gt;160 mmHg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/67\">",
"       67",
"      </a>",
"      ]. Patients were randomly assigned to either antihypertensive therapy (target SBP 145 to 155 mmHg) or placebo within 36 hours of symptom onset. There was no significant difference in early neurologic deterioration at 72 hours between the antihypertensive treatment and placebo groups (6 versus 5 percent, relative risk 1.22, 95% CI 0.33-4.54). However, there were few outcome events, and confidence intervals were wide. In addition, the trial excluded some patients on pre-existing antihypertensive therapy, a group that might be expected to deteriorate with blood pressure lowering in the early phases of ischemic stroke.",
"     </li>",
"     <li>",
"      Similarly, the assessor-blind COSSACS trial enrolled adults on antihypertensive medications within 48 hours of ischemic or hemorrhagic stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/68\">",
"       68",
"      </a>",
"      ]. Patients were randomly assigned to either continue or stop antihypertensive drugs. At two weeks, there was no significant difference between groups for the primary outcome of death or dependency; the difference between the &lsquo;continue&rsquo; and &lsquo;stop&rsquo; groups for systolic (13 mmHg) and diastolic (8 mmHg) blood pressure was significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of these trials are not definitive. All three included patients with intracerebral hemorrhage, a group that might be expected to benefit from early blood pressure lowering. In addition, treatment at earlier time points (eg, within the first 12 hours) after ischemic stroke onset, when patients might be more susceptible to deterioration with blood pressure lowering, may have been under-represented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Blood pressure goals ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations apply to blood pressure control in patients with acute ischemic stroke who are eligible for thrombolytic therapy. Before lytic therapy is started, treatment is recommended so that systolic blood pressure is &le;185 mmHg and diastolic blood pressure is &le;110 mmHg (",
"    <a class=\"graphic graphic_table graphicRef50725 \" href=\"mobipreview.htm?33/29/34268\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. The blood pressure should be stabilized and maintained at or below",
"    <span class=\"nowrap\">",
"     180/105",
"    </span>",
"    mmHg for at least 24 hours after thrombolytic treatment. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link&amp;anchor=H551003#H551003\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Management of blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with ischemic stroke who are not treated with thrombolytic therapy, most consensus guidelines recommend that blood pressure",
"    <strong>",
"     not",
"    </strong>",
"    be treated acutely unless the hypertension is extreme (systolic blood pressure &gt;220 mmHg or diastolic blood pressure &gt;120 mmHg), or the patient has active ischemic coronary disease, heart failure, aortic dissection, hypertensive encephalopathy, acute renal failure, or",
"    <span class=\"nowrap\">",
"     pre-eclampsia/eclampsia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2,69\">",
"     2,69",
"    </a>",
"    ]. When treatment is indicated, cautious lowering of blood pressure by approximately 15 percent during the first 24 hours after stroke onset is suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood pressure management in acute ischemic stroke remains controversial. Current guidelines suggest that antihypertensive medications should be restarted at approximately 24 hours after stroke onset in patients with preexisting hypertension who are neurologically stable, unless a specific contraindication to restarting treatment is known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. However, patients with extracranial or intracranial large artery stenoses may require a slower reduction in blood pressure (eg, over 7 to 10 days after ischemic stroke), as some degree of blood pressure elevation may be necessary to maintain cerebral blood flow to ischemic brain regions.",
"   </p>",
"   <p>",
"    If acute antihypertensive therapy is needed, intravenous agents are generally used. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Choice of antihypertensive agent'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Current guidelines note that vasopressors may be used to improve cerebral blood flow in rare cases when systemic hypotension is producing neurologic impairment, with close neurologic and cardiac monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. At present, drug-induced hypertension is not recommended for the treatment of most patients with ischemic stroke outside the setting of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), the approach to blood pressure management must take into account the potential benefits (eg, reducing further bleeding) and risks (eg, reducing cerebral perfusion) of blood pressure lowering:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reducing the blood pressure in patients with either ICH or SAH may be beneficial by minimizing further bleeding and continued vascular damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with an intracranial hemorrhage due to ICH or SAH may have increased intracranial pressure (ICP) due to blood within the cranium. Cerebral perfusion pressure (CPP) equals MAP minus ICP. Thus, increases in MAP may be the only means to maintain CPP above 60 to 70 mmHg, the level necessary to maintain perfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. Measuring intracranial pressure directly allows blood pressure to be reduced as low as possible while still maintaining the cerebral perfusion pressure above the conservative level of 60 mmHg. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for blood pressure management in acute ICH and SAH are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Intracranial pressure and blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Choice of antihypertensive agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the acute phase of stroke, there is no clear evidence to support the use of any specific antihypertensive agent to achieve recommended blood pressure goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ]. Nevertheless, reversible and titratable intravenous agents are best suited for precise blood pressure lowering. Consensus guidelines suggest intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    as first-line antihypertensive agents if pharmacologic therapy is necessary in the acute phase, since they allow rapid and safe titration to the goal blood pressure&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef50725 \" href=\"mobipreview.htm?33/29/34268\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    should be considered second-line therapy since it carries added theoretical risks of increasing intracranial pressure or affecting platelet function, but in fact it is often needed. Medications likely to cause a prolonged or precipitous decline in blood pressure (eg, rapid-acting formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) should be avoided. In addition, their use is associated with an increased risk of stroke, particularly in elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ACUTE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For eligible patients (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"     table 2",
"    </a>",
"    ) with acute ischemic stroke, we recommend intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    therapy, provided that treatment is initiated within 3 hours of clearly defined symptom onset. For patients who cannot be treated in less than 3 hours, we suggest intravenous alteplase therapy, provided that treatment is initiated within 3 to 4.5 hours of clearly defined symptom onset. The eligibility criteria and utility of thrombolytic therapy as well as the treatment of patients not eligible for thrombolysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10064197\">",
"    <span class=\"h2\">",
"     Ischemic stroke management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to intravenous thrombolysis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , a number of interventions for ischemic stroke are associated with either reduced disability, complications, or stroke recurrence, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antithrombotic therapy initiated within 48 hours of stroke onset (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link&amp;anchor=H3#H3\">",
"       \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Aspirin'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prophylaxis for deep venous thrombosis and pulmonary embolism (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H6#H6\">",
"       \"Medical complications of stroke\", section on 'VTE prophylaxis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antithrombotic therapy at discharge (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"       \"Antiplatelet therapy for secondary prevention of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lipid lowering therapy initiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/75\">",
"       75",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"       \"Secondary prevention of stroke: Risk factor reduction\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H566306634\">",
"       'Statin therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Blood pressure reduction, once the acute phase of ischemic stroke has passed (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17305?source=see_link\">",
"       \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"       \"Secondary prevention of stroke: Risk factor reduction\"",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      Management of blood pressure in the acute phase of ischemic stroke is discussed above (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Blood pressure management'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Smoking cessation along with management of obesity, diabetes, and metabolic syndrome are unproven but generally recommended as well (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"       \"Secondary prevention of stroke: Risk factor reduction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate and timely use of these therapies should be considered as soon as ischemic stroke is recognized. Utilization of these interventions may be improved by the use of standardized stroke care orders or critical pathways beginning with hospital admission through discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2,76\">",
"     2,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H31#H31\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Disease management programs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H566306634\">",
"    <span class=\"h3\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive lipid-lowering therapy with a statin is associated with a reduced risk of recurrent stroke and cardiovascular events, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H13#H13\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Statin therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link&amp;anchor=H35#H35\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Cholesterol and statin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue involves patients on statin therapy at the time of acute stroke. This issue was directly addressed in a single-center randomized controlled trial of 89 patients who were already treated with a statin and were assigned to continuation or cessation of statin therapy in the acute phase of ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/77\">",
"     77",
"    </a>",
"    ]. The rate of death or dependency at three months was significantly lower with continuation of statin treatment (39 versus 60 percent). The largest observational study, which evaluated over 12,000 subjects hospitalized with ischemic stroke, found that statin use before and during hospitalization was associated with improved outcome at hospital discharge and with improved survival at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Furthermore, initiation of statin treatment early in hospitalization was associated with improved survival, while statin discontinuation early in hospitalization, even for a short period, was associated with decreased survival. Likewise, another uncontrolled study of 448 patients reported that new or continued statin treatment in the first 72 hours after acute ischemic stroke was associated with improved early and late (one-year) survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/80\">",
"     80",
"    </a>",
"    ]. Benefit with continued statin therapy was also noted in a mouse model of acute ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon limited information, we suggest continuing statin treatment for patients receiving statin therapy prior to ischemic stroke onset. This suggestion is in accord with current guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87745915\">",
"    <span class=\"h3\">",
"     SSRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence from small randomized controlled trials suggesting that early initiation of selective serotonin-reuptake inhibitors (SSRIs) after ischemic stroke for patients with hemiparesis but without depression enhances motor recovery and reduces dependency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. However, it is unclear if this apparent benefit occurs through a reduction in poststroke depression or some other mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. Larger trials are needed to determine the role of SSRIs for promoting recovery after ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10064162\">",
"    <span class=\"h2\">",
"     Intracranial hemorrhage management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with intracerebral hemorrhage or subarachnoid hemorrhage is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticoagulant use is a common cause of intracerebral hemorrhage. It cannot be overemphasized that the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    need to be corrected as soon as possible in patients with intracerebral hemorrhage. There is a high likelihood that the hemorrhage will enlarge and the patient will deteriorate if this is not done. Management requires intravenous vitamin K, prothrombin-complex concentrates, fresh frozen plasma, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    , and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The direct thrombin inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    and the factor Xa inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    are newer anticoagulants that are used for stroke prevention in patients with atrial fibrillation. There are no specific antidotes to reverse the anticoagulant effects of these agents, and there are few data to guide management in the event of major bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/87\">",
"     87",
"    </a>",
"    ]. Their anticoagulant effects dissipate and should be negligible after 3 half-lives from the last dose, though half-lives are typically prolonged in patients who are elderly or have impaired renal function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      , suggestions for reversal include drug discontinuation, dialysis, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      to remove the unabsorbed drug from the gastrointestinal tract, and activated Factor VII and prothrombin complex concentrates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"       \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      , suggestions for reversal include drug discontinuation, charcoal hemofiltration,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      to remove unabsorbed drug from the gastrointestinal tract, and the use of unactivated or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/61/37844?source=see_link\">",
"       activated prothrombin complex concentrates",
"      </a>",
"      . Both rivaroxaban and apixaban are highly protein bound and therefore not amenable to removal by dialysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H11071512#H11071512\">",
"       \"Anticoagulants other than heparin and warfarin\", section on 'Reversal of rivaroxaban activity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neuroprotective treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous neuroprotective agents have shown promising results in animal experiments. However, clinical trials have thus far failed to confirm consistent benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/88-91\">",
"     88-91",
"    </a>",
"    ]. This failure may be due, at least in part, to limitations of animal models of acute stroke and to shortcomings of clinical trials.",
"   </p>",
"   <p>",
"    The search for effective neuroprotective treatment continues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/90,92\">",
"     90,92",
"    </a>",
"    ]. An updated list of all clinical trials for acute stroke, both in progress and completed, is available online at the",
"    <a class=\"external\" href=\"file://www.strokecenter.org/trials\">",
"     Internet Stroke Center Trials Registry",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVENTION OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of medical complications of stroke is an important goal of stroke management, and this aspect of care begins with initial evaluation of the patient. Common acute and subacute medical problems associated with stroke include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocardial infarction",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Aspiration pneumonia",
"     </li>",
"     <li>",
"      Urinary tract infection",
"     </li>",
"     <li>",
"      Deep vein thrombosis",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Dehydration",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Pressure sores",
"     </li>",
"     <li>",
"      Orthopedic complications and contractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevention, impact, and management of these complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link\">",
"     \"Medical complications of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26952?source=see_link\">",
"     \"Cardiac complications of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10087?source=see_link\">",
"     \"Stroke-related pulmonary complications and abnormal respiratory patterns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delirium, characterized by a disturbance of consciousness with decreased attention and disorganized thinking, is another potential complication of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/93\">",
"     93",
"    </a>",
"    ]. In a meta-analysis of 10 prospective cohort studies, the incidence of post-stroke delirium ranged from 10 to 28 percent after the exclusion of one outlier study with a much higher rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/94\">",
"     94",
"    </a>",
"    ]. Patients with delirium had longer hospital stays and higher inpatient and 12-month mortality rates. Risk factors for developing post-stroke delirium include preexisting cognitive decline, infection, and greater stroke severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/29/33242/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=see_link\">",
"       \"Patient information: Ischemic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94773002\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main goals in the initial phase of acute stroke management are to ensure medical stability, to quickly reverse conditions that are contributing to the patient's problem, to determine if patients with acute ischemic stroke are candidates for thrombolytic therapy, and to begin to uncover the pathophysiologic basis of the neurologic symptoms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of acute stroke evaluation and management include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Assessing vital signs and ensuring stabilization of airway, breathing, and circulation (see",
"      <a class=\"local\" href=\"#H66230911\">",
"       'Airway, breathing and circulation'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Obtaining a rapid but accurate history and examination to help distinguish between ischemic and hemorrhage stroke, and other disorders in the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef69869 \" href=\"mobipreview.htm?26/51/27451\">",
"       table 1",
"      </a>",
"      ) of acute stroke (see",
"      <a class=\"local\" href=\"#H4\">",
"       'History and physical'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H95636670\">",
"       'Neurologic evaluation'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Obtaining emergent brain imaging (with CT or MRI) and other important laboratory studies, including cardiac monitoring during the first 24 hours after the onset of ischemic stroke (see",
"      <a class=\"local\" href=\"#H95644450\">",
"       'Immediate laboratory studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H95646379\">",
"       'Neuroimaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H95646729\">",
"       'Cardiac studies'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Checking serum glucose. Low serum glucose (&lt;60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 3.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      should be corrected rapidly. Normoglycemia is the desired goal while avoiding marked elevation of serum glucose. For patients who have elevated serum glucose concentrations &gt;180",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;10",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      we suggest treatment with insulin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Assessing swallowing and preventing aspiration (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Swallowing assessment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H11#H11\">",
"       \"Medical complications of stroke\", section on 'Dysphagia and aspiration'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Optimizing head of bed position with respect to the risk of elevated intracranial pressure, aspiration, and the presence of comorbid cardiopulmonary disease; for patients in the acute phase of stroke who are at risk for elevated intracranial pressure, aspiration, cardiopulmonary decompensation, or oxygen desaturation, we recommend keeping the head in neutral alignment with the body and elevating the head of the bed to 30 degrees (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ); for patients in the acute phase of stroke who are not at risk for elevated intracranial pressure, aspiration, or worsening cardiopulmonary status, we suggest keeping the head of bed flat (0 to 15 degree head-of-bed position) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Head and body position'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Evaluating and treating the source of fever; for patients with acute stroke, we suggest maintaining normothermia for at least the first several days after an acute stroke (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Fever'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of blood pressure in acute stroke depends on the type of stroke. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Blood pressure management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with acute ischemic stroke who will receive thrombolytic therapy, antihypertensive treatment is recommended so that systolic blood pressure is &le;185 mmHg and diastolic blood pressure is &le;110 mmHg (",
"      <a class=\"graphic graphic_table graphicRef50725 \" href=\"mobipreview.htm?33/29/34268\">",
"       table 6",
"      </a>",
"      ). This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link&amp;anchor=H551003#H551003\">",
"       \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\", section on 'Management of blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with acute ischemic stroke who are",
"      <strong>",
"       not",
"      </strong>",
"      treated with thrombolytic therapy, we suggest treating high blood pressure only if the hypertension is extreme (systolic blood pressure &gt;220 mmHg or diastolic blood pressure &gt;120 mmHg), or if the patient has another clear indication (active ischemic coronary disease, heart failure, aortic dissection, hypertensive encephalopathy, acute renal failure, or",
"      <span class=\"nowrap\">",
"       pre-eclampsia/eclampsia)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When treatment is indicated, we suggest cautious lowering of blood pressure by approximately 15 percent during the first 24 hours after stroke onset (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Blood pressure goals ischemic stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In both intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), the approach to blood pressure lowering must account for the potential benefits (eg, reducing further bleeding) and risks (eg, reducing cerebral perfusion). Recommendations for blood pressure management in acute ICH and SAH are discussed in detail separately (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Intracranial hemorrhage'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"       \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Intracranial pressure and blood pressure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For eligible patients (",
"      <a class=\"graphic graphic_table graphicRef71462 \" href=\"mobipreview.htm?31/40/32397\">",
"       table 2",
"      </a>",
"      ) with acute ischemic stroke, we recommend intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      therapy, provided that treatment is initiated within 3 hours of clearly defined symptom onset. For patients who cannot be treated in less than 3 hours, we suggest intravenous alteplase therapy, provided that treatment is initiated within 3 to 4.5 hours of clearly defined symptom onset. The eligibility criteria and utility of thrombolytic therapy as well as the treatment of patients not eligible for thrombolysis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=see_link\">",
"       \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"       \"Reperfusion therapy for acute ischemic stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"       \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      treatment, a number of interventions for ischemic stroke are associated with either reduced disability, complications, or stroke recurrence, including (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Acute therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antithrombotic therapy initiated within 48 hours of stroke onset. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link&amp;anchor=H3#H3\">",
"       \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylaxis for deep venous thrombosis and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=see_link&amp;anchor=H6#H6\">",
"       \"Medical complications of stroke\", section on 'VTE prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients receiving statin therapy prior to stroke onset, we suggest continuing statin treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H566306634\">",
"       'Statin therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/1\">",
"      Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/2\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/3\">",
"      Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 1997; 28:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/4\">",
"      Kothari R, Hall K, Brott T, Broderick J. Early stroke recognition: developing an out-of-hospital NIH Stroke Scale. Acad Emerg Med 1997; 4:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/5\">",
"      Goldstein LB, Simel DL. Is this patient having a stroke? JAMA 2005; 293:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/6\">",
"      Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997; 28:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/7\">",
"      Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/8\">",
"      Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/9\">",
"      Michaels AD, Spinler SA, Leeper B, et al. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation 2010; 121:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/10\">",
"      Liao J, Khalid Z, Scallan C, et al. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 2007; 38:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/11\">",
"      Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997; 314:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/12\">",
"      Bruno A, Biller J, Adams HP Jr, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999; 52:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/13\">",
"      Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/14\">",
"      Dave JA, Engel ME, Freercks R, et al. Abnormal glucose metabolism in non-diabetic patients presenting with an acute stroke: prospective study and systematic review. QJM 2010; 103:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/15\">",
"      B&eacute;jot Y, Aboa-Eboul&eacute; C, Hervieu M, et al. The deleterious effect of admission hyperglycemia on survival and functional outcome in patients with intracerebral hemorrhage. Stroke 2012; 43:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/16\">",
"      Allport L, Baird T, Butcher K, et al. Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. Diabetes Care 2006; 29:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/17\">",
"      Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke 2004; 35:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/18\">",
"      Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 2002; 52:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/19\">",
"      Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002; 59:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/20\">",
"      European Stroke Initiative Executive Committee, EUSI Writing Committee, Olsen TS, et al. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis 2003; 16:311.",
"     </a>",
"    </li>",
"    <li>",
"     Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial. file://clinicaltrials.gov/ct2/show/NCT01369069 (Accessed on March 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/22\">",
"      Bruno A, Durkalski VL, Hall CE, et al. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/23\">",
"      Bellolio MF, Gilmore RM, Stead LG. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev 2011; :CD005346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/24\">",
"      Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke 2002; 33:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/25\">",
"      Wojner-Alexander AW, Garami Z, Chernyshev OY, Alexandrov AV. Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology 2005; 64:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/26\">",
"      Toole JF. Effects of change of head, limb and body position on cephalic circulation. N Engl J Med 1968; 279:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/27\">",
"      Caplan LR, Sergay S. Positional cerebral ischaemia. J Neurol Neurosurg Psychiatry 1976; 39:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/28\">",
"      Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a prospective review. Stroke 1984; 15:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/29\">",
"      Frank JI. Large hemispheric infarction, deterioration, and intracranial pressure. Neurology 1995; 45:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/30\">",
"      Hacke W, Schwab S, Horn M, et al. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996; 53:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/31\">",
"      Rowat AM, Wardlaw JM, Dennis MS, Warlow CP. Patient positioning influences oxygen saturation in the acute phase of stroke. Cerebrovasc Dis 2001; 12:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/32\">",
"      Tyson SF, Nightingale P. The effects of position on oxygen saturation in acute stroke: a systematic review. Clin Rehabil 2004; 18:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/33\">",
"      Summers D, Leonard A, Wentworth D, et al. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association. Stroke 2009; 40:2911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/34\">",
"      Fern&aacute;ndez-Crehuet R, D&iacute;az-Molina C, de Irala J, et al. Nosocomial infection in an intensive-care unit: identification of risk factors. Infect Control Hosp Epidemiol 1997; 18:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/35\">",
"      Ginsberg MD, Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke 1998; 29:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/36\">",
"      Greer DM, Funk SE, Reaven NL, et al. Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke 2008; 39:3029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/37\">",
"      Saini M, Saqqur M, Kamruzzaman A, et al. Effect of hyperthermia on prognosis after acute ischemic stroke. Stroke 2009; 40:3051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/38\">",
"      Phipps MS, Desai RA, Wira C, Bravata DM. Epidemiology and outcomes of fever burden among patients with acute ischemic stroke. Stroke 2011; 42:3357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/39\">",
"      Prasad K, Krishnan PR. Fever is associated with doubling of odds of short-term mortality in ischemic stroke: an updated meta-analysis. Acta Neurol Scand 2010; 122:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/40\">",
"      den Hertog HM, van der Worp HB, van Gemert HM, et al. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 2009; 8:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/41\">",
"      Den Hertog HM, van der Worp HB, Tseng MC, Dippel DW. Cooling therapy for acute stroke. Cochrane Database Syst Rev 2009; :CD001247.",
"     </a>",
"    </li>",
"    <li>",
"     The Intravascular Cooling in the Treatment of Stroke 2/3 Trial (ICTuS2/3). file://clinicaltrials.gov/ct2/show/NCT01123161 (Accessed on June 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/43\">",
"      Candelise L, Gattinoni M, Bersano A, et al. Stroke-unit care for acute stroke patients: an observational follow-up study. Lancet 2007; 369:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/44\">",
"      Meretoja A, Roine RO, Kaste M, et al. Effectiveness of primary and comprehensive stroke centers: PERFECT stroke: a nationwide observational study from Finland. Stroke 2010; 41:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/45\">",
"      Di Carlo A, Lamassa M, Wellwood I, et al. Stroke unit care in clinical practice: an observational study in the Florence center of the European Registers of Stroke (EROS) Project. Eur J Neurol 2011; 18:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/46\">",
"      Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition. Stroke 2011; 42:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/47\">",
"      Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 2005; 36:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/48\">",
"      Alberts MJ. Stroke centers: proof of concept and the concept of proof. Stroke 2010; 41:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/49\">",
"      Middleton S, McElduff P, Ward J, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet 2011; 378:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/50\">",
"      European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/51\">",
"      Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation 2008; 118:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/52\">",
"      Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke 2009; 40:2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/53\">",
"      Wallace JD, Levy LL. Blood pressure after stroke. JAMA 1981; 246:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/54\">",
"      Leonardi-Bee J, Bath PM, Phillips SJ, et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/55\">",
"      Okumura K, Ohya Y, Maehara A, et al. Effects of blood pressure levels on case fatality after acute stroke. J Hypertens 2005; 23:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/56\">",
"      Bath PM. How to manage blood pressure in acute stroke. J Hypertens 2005; 23:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/57\">",
"      Berge E. Should high blood pressure be lowered in the acute stroke? J Hypertens 2011; 29:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/58\">",
"      Oliveira-Filho J, Silva SC, Trabuco CC, et al. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology 2003; 61:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/59\">",
"      Vlcek M, Schillinger M, Lang W, et al. Association between course of blood pressure within the first 24 hours and functional recovery after acute ischemic stroke. Ann Emerg Med 2003; 42:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/60\">",
"      Castillo J, Leira R, Garc&iacute;a MM, et al. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004; 35:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/61\">",
"      Mistri AK, Robinson TG, Potter JF. Pressor therapy in acute ischemic stroke: systematic review. Stroke 2006; 37:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/62\">",
"      Rordorf G, Cramer SC, Efird JT, et al. Pharmacological elevation of blood pressure in acute stroke. Clinical effects and safety. Stroke 1997; 28:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/63\">",
"      Rordorf G, Koroshetz WJ, Ezzeddine MA, et al. A pilot study of drug-induced hypertension for treatment of acute stroke. Neurology 2001; 56:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/64\">",
"      Hillis AE, Barker PB, Beauchamp NJ, et al. Restoring blood pressure reperfused Wernicke's area and improved language. Neurology 2001; 56:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/65\">",
"      Marzan AS, Hungerb&uuml;hler HJ, Studer A, et al. Feasibility and safety of norepinephrine-induced arterial hypertension in acute ischemic stroke. Neurology 2004; 62:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/66\">",
"      Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/67\">",
"      Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009; 8:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/68\">",
"      Robinson TG, Potter JF, Ford GA, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010; 9:767.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Stroke: The diagnosis and acute management of stroke and transient ischaemic attacks. Royal College of Physicians, London 2008. file://www.nice.org.uk/CG068 (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/70\">",
"      Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Trust Study Group. Lancet 1990; 336:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/71\">",
"      Thrift AG, McNeil JJ, Forbes A, Donnan GA. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 1998; 31:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/72\">",
"      Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/73\">",
"      Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/74\">",
"      Jung SY, Choi NK, Kim JY, et al. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology 2011; 77:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/75\">",
"      Yeh PS, Lin HJ, Bai CH, et al. Effect of in-hospital initiation of lipid-lowering therapy on six-month outcomes in patients with acute ischemic stroke or transient ischemic attack. Am J Cardiol 2010; 105:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/76\">",
"      California Acute Stroke Pilot Registry Investigators. The impact of standardized stroke orders on adherence to best practices. Neurology 2005; 65:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/77\">",
"      Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007; 69:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/78\">",
"      Flint AC, Kamel H, Navi BB, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012; 43:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/79\">",
"      Flint AC, Kamel H, Navi BB, et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology 2012; 78:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/80\">",
"      N&iacute; Chr&oacute;in&iacute;n D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke 2011; 42:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/81\">",
"      Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/82\">",
"      Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012; 11:CD009286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/83\">",
"      Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/84\">",
"      Chollet F. Selective serotonin reuptake inhibitors may be helpful in most patients with stroke. Stroke 2012; 43:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/85\">",
"      Marshall RS. Should every patient with stroke be on selective serotonin reuptake inhibitors? No. Stroke 2012; 43:3152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/86\">",
"      Selim MH, Molina CA. Poststroke treatment with selective serotonin reuptake inhibitors: a journey from sadness to motor recovery. Stroke 2012; 43:3154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/87\">",
"      Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013; 35:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/88\">",
"      D&aacute;valos A, Alvarez-Sab&iacute;n J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/89\">",
"      Reza Noorian A, Nogueira R, Gupta R. Neuroprotection in acute ischemic stroke. J Neurosurg Sci 2011; 55:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/90\">",
"      Sahota P, Savitz SI. Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 2011; 8:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/91\">",
"      Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients?: yes, but not the way we tried it before. Stroke 2010; 41:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/92\">",
"      Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012; 11:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/93\">",
"      Balami JS, Chen RL, Grunwald IQ, Buchan AM. Neurological complications of acute ischaemic stroke. Lancet Neurol 2011; 10:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/94\">",
"      Shi Q, Presutti R, Selchen D, Saposnik G. Delirium in acute stroke: a systematic review and meta-analysis. Stroke 2012; 43:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/29/33242/abstract/95\">",
"      Oldenbeuving AW, de Kort PL, Jansen BP, et al. Delirium in the acute phase after stroke: incidence, risk factors, and outcome. Neurology 2011; 76:993.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1126 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33242=[""].join("\n");
var outline_f32_29_33242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H94773002\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66230911\">",
"      Airway, breathing and circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95636670\">",
"      Neurologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95644450\">",
"      Immediate laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95646379\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95646729\">",
"      - Cardiac studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100189574\">",
"      STROKE MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100191313\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100191613\">",
"      Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Swallowing assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Head and body position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68922375\">",
"      Stroke unit care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BLOOD PRESSURE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Blood pressure goals ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Choice of antihypertensive agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ACUTE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10064197\">",
"      Ischemic stroke management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H566306634\">",
"      - Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87745915\">",
"      - SSRIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10064162\">",
"      Intracranial hemorrhage management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neuroprotective treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVENTION OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94773002\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1126|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/5/88\" title=\"figure 1\">",
"      Headache and vomiting in stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1126|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/51/27451\" title=\"table 1\">",
"      Acute stroke differential dx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/40/32397\" title=\"table 2\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/15/27900\" title=\"table 3\">",
"      Acute stroke syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/33/40477\" title=\"table 4\">",
"      NIH Stroke Scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/2/21548\" title=\"table 5\">",
"      Outcome of placebo group NINDS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/29/34268\" title=\"table 6\">",
"      Treating hypertension in acute ischemic stroke",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26952?source=related_link\">",
"      Cardiac complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/37/36439?source=related_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17610?source=related_link\">",
"      Medical complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/53/19286?source=related_link\">",
"      Patient information: Ischemic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10087?source=related_link\">",
"      Stroke-related pulmonary complications and abnormal respiratory patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_29_33243="USPSTF recommendation grade";
var content_f32_29_33243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    USPSTF grading scheme for recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The U.S. Preventive Services Task Force (USPSTF) grades",
"its recommendations according to one of five classifications (A, B, C,",
"D, I) reflecting the strength of evidence and magnitude of net benefit",
"(benefits minus harms).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. The USPSTF strongly recommends that clinicians",
"provide [the service] to eligible patients. The USPSTF found good",
"evidence that [the service] improves important health outcomes and",
"concludes that benefits substantially outweigh harms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. The USPSTF recommends that clinicians provide [this",
"service] to eligible patients. The USPSTF found at least fair evidence",
"that [the service] improves important health outcomes and concludes",
"that benefits outweigh harms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. The USPSTF makes no recommendation for or against",
"routine provision of [the service]. The USPSTF found at least fair",
"evidence that [the service] can improve health outcomes but concludes",
"that the balance of benefits and harms is too close to justify a",
"general recommendation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. The USPSTF recommends against routinely providing",
"[the service] to asymptomatic patients. The USPSTF found at least fair",
"evidence that [the service] is ineffective or that harms outweigh",
"benefits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I. The USPSTF concludes that the evidence is",
"insufficient to recommend for or against routinely providing [the",
"service]. Evidence that the [service] is effective is lacking, of poor",
"quality, or conflicting and the balance of benefits and harms cannot be",
"determined.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From U.S. Preventive Services Task Force Ratings: Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000- 2003. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/3rduspstf/ratings.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33243=[""].join("\n");
var outline_f32_29_33243=null;
var title_f32_29_33244="Advantages and disadvantages of treatment in nontoxic MNG";
var content_f32_29_33244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of the treatment options in nontoxic multinodular goiter",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Surgery",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Significant goiter reduction",
"        </p>",
"        <p>",
"         Rapid decompression of trachea",
"        </p>",
"        <p>",
"         Prompt relief of symptoms",
"        </p>",
"        <p>",
"         Definite histological diagnosis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Inpatient",
"        </p>",
"        <p>",
"         High cost",
"        </p>",
"        <p>",
"         Surgical risk",
"        </p>",
"        <p>",
"         Vocal cord paralysis: ~1 percent",
"        </p>",
"        <p>",
"         Hypoparathyroidism: ~1 percent",
"        </p>",
"        <p>",
"         Risk of hypothyroidism dependent of resection",
"        </p>",
"        <p>",
"         Risk of recurrence dependent of resection",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         <sup>",
"          131",
"         </sup>",
"         I",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Most often outpatient",
"        </p>",
"        <p>",
"         If outpatient: low cost",
"        </p>",
"        <p>",
"         Few subjective side effects",
"        </p>",
"        <p>",
"         Goiter reduction: 50 percent within 1 yr",
"        </p>",
"        <p>",
"         Improves inspiratory capacity in long term",
"        </p>",
"        <p>",
"         Can be repeated successfully",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Limitation of administrated radioactivity",
"        </p>",
"        <p>",
"         Restricted proximity to other persons",
"        </p>",
"        <p>",
"         Contraceptives needed in fertile women",
"        </p>",
"        <p>",
"         Gradual reduction of the goiter",
"        </p>",
"        <p>",
"         Decreasing effect with increasing size",
"        </p>",
"        <p>",
"         Small risk of acute goiter enlargement",
"        </p>",
"        <p>",
"         Risk of thyroiditis: 3 percent",
"        </p>",
"        <p>",
"         Risk of transition into Graves' disease: 5 percent",
"        </p>",
"        <p>",
"         1 yr risk of hypothyroidism: 15 to 20 percent",
"        </p>",
"        <p>",
"         Long-term cancer risk unknown",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         <span class=\"small\">",
"          L",
"         </span>",
"         -T",
"         <sub>",
"          4",
"         </sub>",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Outpatient",
"        </p>",
"        <p>",
"         Low cost",
"        </p>",
"        <p>",
"         May prevent new nodule formation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Low efficacy",
"        </p>",
"        <p>",
"         Lifelong treatment",
"        </p>",
"        <p>",
"         Adverse effects (bone, heart)",
"        </p>",
"        <p>",
"         Not feasible when TSH is suppressed",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Heged&uuml;s L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24:102. Copyright &copy; 2003 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33244=[""].join("\n");
var outline_f32_29_33244=null;
var title_f32_29_33245="A2 and autoregulation of GFR";
var content_f32_29_33245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Role of angiotensin II in autoregulation of GFR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 217px; background-image: url(data:image/gif;base64,R0lGODlhvgHZANUAAP///4CAgAAAAP8AAMDAwEBAQAAzmYCZzCAgIDAwMBAQEKCgoHBwcNDQ0PDw8ODg4FBQULCwsP+AgGBgYJCQkP+goP/AwP9AQP9QUP8gIP/w8P/g4MDN5v9gYP8QEP/Q0PDz+TBZrP+wsP+QkGCAv/8wMEBms/9wcNDZ7BBAn6Cz2V8fXy8pfL+Mpq8PL6+Pr78MJs96jVBzuT8mcnCNxoBJfIBZjCBNpp+TuQAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAC+AdkAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/dxwHw8TFHGDCxcrHX8nKxMzAmwQNQw4LAQsOQxEBFA+sBwbj5OUHYOIGLC4D7QMuLOdf4uvu7ywG8tKYDQECBUMS/BOQQAgDggoUgFOVrpw5dAZW2LMXA53Eie1W6NtnqYCAf0IiCIAAAIKACA4EKABAQQCDVQ0djtvI5cAMjPYsfGmB010L/46ZCIAE4C8AUQEBhAJUKoRAgKdQCYSKKdPEs6tYsw4zAaNnuxISwoodS7asWbElvA64wMYp1Ldw48qdS7eu3bt48+rNKzUN06NGizL96xZqAaOgqDq0qrWxVhNq252dTHls5AFsAhzey7mz58+gOx9W87fly4MUGhAEIJLkkadTZT78guOylw2218CWtvtMg5YJCDh4IAABAQQCwCGPYHIBkt6eFM/ussFG7i7X00D3tZ2Mx48CpC5AjsA5gAYCFbx8jviTDNnkaGKxcMFDja5e2Xq5oFa/mu68AOiHgJiQAF98W1RQggcSaGCTWjp5wZNXP+nW3i8E8pFhJSSEQP/DgflgoUEFGWRQwRDiXIRRRfOoOJFGmV3InYyAbDhJhyA4c1U0U2gggQcXiFBEMi9gYA8GL/DIhTBFHvnCAUqeYSMROj4TJShT4pGlIyCYEAIIYWzQwQAdRJjKlgBIhyAUD1CQzTZeMACQG2jK4dZomoAQwpdgWICBBx1s0Aqaas4ExQLgDdWER04wSieNfNwJ6SR6kgBGBfU1+AqhIMqXBHEKSNUPAA7IOUE1DwQQgZxGHYcUAU41sIBUzBVAgRCOtlEnHbseUukXJJqoQSwCVrkViIxBk4RpRSSgQADOPiDUPwoIsMAC1RaAjUpItXbQS7nGWEivhaBwg6Vc+Aj/5ImzFHuVCcguk0RRRKj2kkgUCGWUSEY56k8EQpi0jbMAhGvhuJM+gkIK6GohpgcYmNluwkcUGqITiM4JgLRIAaCvvh537G94uApQcsEmP4qwJQursIUFYwaKC6cHepoEcodBAJACxpnUAMggexRBPySz1O1IKL9BLhfXqDoErFDPS/EiLWshQqbD5kIzfDYj8YBJxd2KXnHOAd1xBNW6WTQADFQLwTYG/zf1EwXUbXcB6y3hgEACrZdoyq/NjYgKKbiMRbAjZK3L1rJ13cnSRfz9kcZKMIscOB9Fzd4kKhhg+BIfGOkOBh8I4WMGJbDbC+MyOc4J5Fn4Ay7Jk0PQ/5fHcOEJCeEoNFFBTyOcAKTEqws+hLHGmAK7ERQUAAHATRBHLckQBDCBSgsV9pTujvDehAX9CbrP8qqQP8RB4EHPRD/jAV7y7UWYbwcNKfTeBH/5ASX/Kft37IDOGCOASV5CgARYTyVwMsL+5kCC+j0hO8BYYCn6Bz05OeEjCEDMAwRCkGpsrhE4egJuIqM/49FifyYpgEBuJQYJviGEUIAghkw4MaaZRD1kcCEbusSnKOCvJ/7hDQ1lsb8GeLAMOlSDnnoYBfB5hXgzHN8Ql1A3KU3xDr+qwu9wojopenELESjIGCT1B+QNIwQywAIG0jK60gGFKFfcVByR8J3Jgf+BjH6wmOuYgBvFvZEISQzF/uRkt7yBIZBd0OMVJNCBPwZOCqE7khuVN8cjNGAhlxwDImvSqStkAIqOrNMWMdJFJzgAVkP4GawacEqoJdANDdAWFPaHJ81ospJpUGQVRJABRz7yCU7sCSiVgD7o1bEA08qcFBSlhVTBbwj+eCYctRBLntVNAZT7wia3oEsqYGAEvlQgDX+IkyA2ATkCmAA0OyaEjxiBkKfCXQQmUACAISqD0tKZrYTgAHo+RSqlKkA8U7Wq0TiTVIQMwAM8MgHzQBOXT/ubAtSnN2yor2nakNofuikFDQxAfOF8KBIsYJbLkGWYIREABaoFJ3q1033/Qshg2xBwFGx+5AEHwWY/JqAZawGgb9czirOgpZBpFaBas+oYAp7FAAQ0ADkJMOQ0t8AAh5qSby4RgkA8IsZf9oGjURgBBkIav0mRlCxjisxJlXC9B1zPPC4FgDuLQAA5VesoUjmIVIbiAApAQCBJSWfIAmAv1qgUZPwCWUJ4Co5oirMLqqRGEyyXnNaU5CQf/GonqZABIZFVpA8koSknB1UhxHWu3BhJGE3mWMcOxVkUaElgW/Wqjn3MtrU1SgMggByFOLasXECfHZkgO5Q5pWMu1Z5mIHoGsAKzl58FrRPIiRFzVi6dT0GOEa93qlNmLoFFiQBy8Ere4hCAOMY5/0gAUpLejvFMgAL4GW5nW7BZeYRoSQHuFlQCFat+anLVOm5g2Klc7u3BuU7ogASiK93vQegJAoHTt46ZzLXtrTjjbS3J/BFfRA3EKNj68HkEUp7BDhZkYCvxA5DjmgZjIYNSYN94mYWazPLBjMO4EhM8CtLoirInpdzDrOBL0S4MEpmrDOAAN2bey9lYE5hisIubEMk2BuJ6xWGuRrdQR2YqAYPtaV+Jn5yJ1EnZtFpGxf6w0d9bduIDHjgzmr/IBcnmMM2C6MAJ5DzVCOK5AdUiyCu1iedAeGCSUt7m4/CMAJkqQJ0tLPQfFMTnPkdxv32x5RfwqIkLBNnHmwmNqP9HTepSz8XAV0CA7cIIaS9wGhMb8IAfpaxcU9v61rjGizSt4GGVHPGQku7DCRpZ6WI/oR/fuPMmDm3sZi8hACRZaJG9oGg68NLZ2EaCAsxDTzdn4pvZDjcRiqZpJjSNAnCCGirJPIk+ivvdCUhABNAmVSRc2CMK2MbftnwJRr773SL5iEKaIJSCeGSv4Vm3Vy3xyX+/O1XJbsKFE4AASNfudgUOdh6u7fCOm3ICPBN0SQ44cNy9BdWSULDHV74E2V72QgdnNyR4zPKaHwFRwRHIrAx4vXzL/BFitXmzM3mehTChbVneGAcT8Gv9VqKzQjd2LbNJbY3bwQLQjbqcq4n/gGtS3chWr4Oetc7nCqtk2mCvhAY80GOyS7mqVqxElN3O5762edPbC/sczEx3OXf561l4NSTg3Hc+EwRqTa86JYZdeDkbMO6TYHbj357Bp/hX8ZKg9OSl/HdvR8LTm5dyZO1sbmygm5/YyOjPExHrWYc+pN1IVeKPcG8E/nQgXX1sJBj/+uiiT4CtVkLBjWtZk6Dd0o5oeO8/++jglFsJE684YKZvcsPo3Q0cXz5Zw4PMbpsb5FB1AL2Sm7vrtwHc2ierClWt0sl2zCTeyGqNF84Id6c/pID+SAIGjQScF9Ba6OUqRud0jeBv9xdS0uJKToB0MAYAYnZ5U6YIUHeA/+GUACThANIXaY+AdRQYUuQGeFtQbWigch3oSwrAQhDQYsDmCDRXgo50PfHmUxrYCEHngo7UTypRb1sgeIkwgTb4RkZEBjx4CIT3g39URWYggmUwdkb4RmEEeYqwdm3XhMDQeTOoCHNHhRxBSHWjg1yghGPAd1pobK2kgOq2a3OmCK03hhwxNsfBQktgdggHHvyGCLzHhtLgLKFiQeYGKx6GOQmHhshnCJKHh8BwEsj0fEzAXS/lPBhXflhYAoa4DydYTxkYPTcVMCSXPZCYCKA3iRGUKIJoBIxYBDFHf4Rgf6D4C83zPE8wLdnDc7aHioNggKv4C6c0e0ngEXmzQf/6p4uDOAjKd4u90Gv753mFkH3EyAs8EwAHEXyEhgjot4zM2Bd8GAZgSB0D4HrUeAvOCCsTYDvAiAXZyAU12I270GXDVWd5dwg+iI65wGZvAYFXMIR/wIHwaHPlqAUkmI8st48i8lH+WHMAeQXnOJAeV5CQJDrtQDoIqQuywn+0d4bbgFESmYZ+MEoT8WkPGQtC8SwXGVGieHtcVYd7EEw4gVId6QpOgXJE0Ep/WHyYRYt4QF0TYV0rGQv0iASMOH4E1ol9IEM5WT4GlQAgaATS01jI9ZMnZ35ZMEJqMZSuEHDTo4JLUIo01n40eQdCKZXKYxxYxgAhSVeZyGTG4WT/W2kHNmkPOOmVE7QUM9koWTUED2iSeoCSGKGSbilIknOUseOUWqCR9sCRezkKHJYofkmOgKkFVdaQiFaYfKaQkMkRCwAQ15KEizmZIeUPBZOY9diOmhl6nImEYWCPoUl2RdFoloeMp9l3hwkenmkFktmavVBrO6kFs0mbUZebupkLspcqTzGAFbUbZ2iXvSl0AYAA3vURxpN/BUBTcpUoxnmcNYc3g0WaS6Bd4xaI00mdK2edscQ2nqkajYY00emITwOU3il0IOdBD/BoBHd4OjdyPceJTbmeWmdU3zGKqQQScWVcq4ef/xZiKnGbRbAcAgErsuhzaSmgDqdwTjA2/9umdL/YnQ46ibx5oeGWoRqKbRzaoc32oSAqZ6Y5okZYoibahCKaome2oizKYC76op8VozJqC02DGBZpoTUqdM4JnVu1GgG6ozWnnSlFEsYXpELqceTJYtNHficXarkWpVI6pVRapaTGn+lXcP+3LQOGGAUGpZxRN6AhpmMKpnpBpp6BpqJhpmfKpnmhpmHqpnjhkhSoGgBRFFkJhwQYBUsDOeTSp3MEqFUgqFRAo2+EoOERgGipe1NAqIUaR44qBZHKp4FaqVoooeZRl0iKBBBKqVbQqU+wNKAaqnM0qk4gqliqo8tYjqyamRGIRK6KkQjZquJyMLYqNytpqkKYqv+bxquu5qtdoKtjBKxJWqzGeqzImqzrc16o9yZjcKPNqnpgcG5wkqObdkTWyhreIJxYQHpt4g0J1A0Rt4NN9zNGJ67ciof5hxg/mnte0KNahXthUHs+167v6g8aY69sgxAlhwVEozF1JEYHoYfpOgX/Wi/VghgDmxAFq4UctC9Ic6RgQKSGZaRxGayrcXAyeXxV8B1zsrEpsRLMkgUeyw0OgIHhEbJG44VSULIBwZykohIru4oBoB5L2aVgsKRI45MaF33qxLOuNhQ8Oxhe9qlFezlEG5vxqTE1q14hA5dKW6cnAbT/WWfyaS1A+wX9FHL7l7VWOydDCxJ/EXhexiz/SbuDQ6Ea3YBbUAuKr4kUeZqz/gm38qeVXuBy8Be3GDsneaoaBWFZWjC2+wppfluxaAu2f0NYqwG4hpiA3PUAipocYYCo59VkkvsF/qdzkduwVPAbhzcclqscJ9Ec1AQcwnFZlScVy0G6WeC5wTEc4JhOosscMkiz7KSpOZsemUoeBnoFDIgYuMtlI6mpEsqyLTuSiTtiOSi84HE7LlW8yhq90ju91Fu91nu92Ju92juscGKudWCdRwC+kCAt2UOs2vsRtyI95le0z0GP7LsILoVa29sEGLSvt1s3LARP1eAU81RPRVCZzgMwzhQB15Jl4ADALJQNo5INHqNPLMRM/wQlJwKcFAS8MfQUTyzRheDQPHjzANggBB8cK7PSwHhzkRZVwvTkQdmgGQuwW29DfXMVAQJlqENZHCcRckbxLSZxK45GU/5gU5cbMAyQnMnxkf+QUwXQADrcftxiMv7JUx7hHMwkFBkkEPKVLe9pQAkBANczxMHRxdBCAI7CKD98NBBwEFY5BB5RnjYFnfpXLQggED/7D0/hTiJhQOM1v0fwDxCQEPTSjPjqMXbFWiSjV0SQKs+ZcHMpV3MCyCABpIxMKn4FWJEcURAbWOvRElAcHiZRPVLRyfk1xoQMPfBHxHRkMkGTMnO7V3cqOSgDDnGjx4wsEkPcMVlmea2xWv/k9VsbowAJsADXAyvsVMm3zMCKAhKw5XJTPF8gcxQ8FZz9xEEoMQHSLMrkhTJvccom5iirHMnxazLWLMuRsxTi936vwmbdkmEbtjZCYTsH18xyZRxfc85GccwAYV5Ou8wT8H/yhRh+GwF11QATkC+oMdB1pVKdjHTX3BKrpk59/EqMksrt1MqsDMMmo17iBVPirCj0srX8dWHluctrw8UqkaDwzGGsBHL8VcmR7GEeUc+UQ8UFamIhsXSpUi04VLPL+1QjIRDXTBToRBLwSQQRLTKqTNHezE7u5ABrnMfiDAnwvAaqwblY4MEEgC3u+tSMENVq0A1jkH8jMY5aPdYmZF3WZn3WaJ3War3WbN3Wbv3WcB3Xcj3XdF3Xdn3XeJ3Xes1yQQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of reducing renal artery pressure (from a baseline value of about 125 mmHg) on&nbsp;glomerular filtrartion rate (GFR), expressed as a percentage of control values in dogs fed a normal sodium diet. The blue squares represent control animals in which both GFR was maintained until the pressure was markedly reduced. The red circles represent animals given an intrarenal infusion of an angiotensin II antagonist; autoregulation of GFR was less well-regulated. Although not shown, autoregulation also applies to GFR when the renal artery pressure is initially raised and to renal blood flow, which is not impaired by inhibiting the activity of angiotensin II.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hall JE, Guyton AC, Jackson TE, et al. Am J Physiol 1977; 233:F366.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33245=[""].join("\n");
var outline_f32_29_33245=null;
var title_f32_29_33246="Quinolone MICs versus GNR I";
var content_f32_29_33246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67649%7EID%2F75299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67649%7EID%2F75299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activity of quinolones against selected gram-negative and other pathogens in vitro-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Organism",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"6\">",
"       Representative MIC",
"       <sub>",
"        90",
"       </sub>",
"       (range), mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Ciprofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Norfloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Levofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Moxifloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Gemifloxacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acinetobacter spp",
"      </td>",
"      <td>",
"       <p>",
"        0.25-2",
"       </p>",
"       <p>",
"        (0.25-&gt;128)",
"       </p>",
"      </td>",
"      <td>",
"       (8-64)",
"      </td>",
"      <td>",
"       <p>",
"        0.25-1",
"       </p>",
"       <p>",
"        (0.25-128)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.4-16",
"       </p>",
"       <p>",
"        (0.12-16)",
"       </p>",
"      </td>",
"      <td>",
"       2-8",
"      </td>",
"      <td>",
"       4-32",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Campylobacter jejuni",
"      </td>",
"      <td>",
"       (0.12-0.78)",
"      </td>",
"      <td>",
"       (0.25-2)",
"      </td>",
"      <td>",
"       (0.12-2)",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlamydia pneumoniae",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.03-1",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlamydia trachomatis",
"      </td>",
"      <td>",
"       1-3.1",
"      </td>",
"      <td>",
"       &ge;16",
"      </td>",
"      <td>",
"       0.5- 1.6",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.03-0.125",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Citrobacter spp",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.03-0.78)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.25-50)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.1-25)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.12-6.25",
"       </p>",
"       <p>",
"        6.25",
"       </p>",
"      </td>",
"      <td>",
"       0.06-2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enterobacter cloacae",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.03-0.5)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (&lt;0.25-2)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.25",
"       </p>",
"       <p>",
"        (0.1-1)",
"       </p>",
"      </td>",
"      <td>",
"       0.12-0.78",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       0.25-1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Escherichia coli",
"      </td>",
"      <td>",
"       <p>",
"        0.06",
"       </p>",
"       <p>",
"        (0.01-0.25)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.01-0.5)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.02-1)",
"       </p>",
"      </td>",
"      <td>",
"       0.05-0.12",
"      </td>",
"      <td>",
"       0.06-1",
"      </td>",
"      <td>",
"       0.016-0.03",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Haemophilus influenzae",
"      </td>",
"      <td>",
"       (0.008-0.06)",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       (0.06-0.5)",
"      </td>",
"      <td>",
"       0.025-0.06",
"      </td>",
"      <td>",
"       0.03-0.06",
"      </td>",
"      <td>",
"       &le;0.004-0.03",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Klebsiella spp",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.02-1)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.2-2)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.25",
"       </p>",
"       <p>",
"        (0.12-1)",
"       </p>",
"      </td>",
"      <td>",
"       0.1-3.1",
"      </td>",
"      <td>",
"       0.12-0.25",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Legionella spp",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       (0.2-2)",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       (0.03-0.25)",
"      </td>",
"      <td>",
"       0.015",
"      </td>",
"      <td>",
"       0.003-0.006",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MIC",
"     <sub>",
"      90",
"     </sub>",
"     : minimal inhibitory concentration for 90 percent of strains.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eliopoulos, GM, Eliopoulos, CT. Activity in vitro of the quinolones. In: Quinolone antimicrobial agents (2nd ed), Hooper, DC, Wolfson, JS (Eds), American Society for Microbiology, Washington, DC, 1993, p. 161, and Wolfson, JS, Hooper, DC, Clin Microbiol Rev 1989; 2:378. Perry, CM, Barman Balfour, JA, Lamb, HM. Drugs 1999; 58:683. Barman Balfour, JA, Wiseman, LR. Drugs 1999; 57:363. Blondeau, JM. J Antimicrob Chemother 1999; 43(SupplB):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activity of quinolones against selected gram-negative and other pathogens in vitro-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Organism",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"6\">",
"       Representative MIC",
"       <sub>",
"        90",
"       </sub>",
"       (range), mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Ciprofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Norfloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Levofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Moxifloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Gemifloxacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Moraxella catarrhalis",
"      </td>",
"      <td>",
"       (0.03-0.25)",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"      <td>",
"       (0.06-0.5)",
"      </td>",
"      <td>",
"       0.06-0.12",
"      </td>",
"      <td>",
"       0.012-0.06",
"      </td>",
"      <td>",
"       &le;0.004-0.015",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycoplasma pneumoniae",
"      </td>",
"      <td>",
"       (1-8)",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       (0.78-2)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.06-0.12",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neisseria gonorrheae",
"      </td>",
"      <td>",
"       0.01",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       0.015-0.1",
"      </td>",
"      <td>",
"       0.015",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neisseria meningitidis",
"      </td>",
"      <td>",
"       (0.008-0.12)",
"      </td>",
"      <td>",
"       0.03",
"      </td>",
"      <td>",
"       (0.06-0.4)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.015",
"      </td>",
"      <td>",
"       0.002",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Proteus mirabilis",
"      </td>",
"      <td>",
"       <p>",
"        0.06",
"       </p>",
"       <p>",
"        (0.03-0.39)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.1",
"       </p>",
"       <p>",
"        (0.12-0.5)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.12-1)",
"       </p>",
"      </td>",
"      <td>",
"       0.06-0.25",
"      </td>",
"      <td>",
"       0.25-2",
"      </td>",
"      <td>",
"       0.12-0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Providencia rettgeri",
"      </td>",
"      <td>",
"       <p>",
"        1.0",
"       </p>",
"       <p>",
"        (0.03-2)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        2",
"       </p>",
"       <p>",
"        (0.25-3.1)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        1",
"       </p>",
"       <p>",
"        (0.5-8)",
"       </p>",
"      </td>",
"      <td>",
"       0.5-3.1",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Providencia stuartii",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.125-2)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        2",
"       </p>",
"       <p>",
"        (0.25-2)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        1",
"       </p>",
"       <p>",
"        (1-8)",
"       </p>",
"      </td>",
"      <td>",
"       0.25-1",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       0.25-16",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pseudomonas aeruginosa",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.25-8)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        2",
"       </p>",
"       <p>",
"        (2-16)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        2",
"       </p>",
"       <p>",
"        (2 - &gt;50)",
"       </p>",
"      </td>",
"      <td>",
"       2-50",
"      </td>",
"      <td>",
"       8 - &ge;32",
"      </td>",
"      <td>",
"       4-8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salmonella spp",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       <p>",
"        0.06",
"       </p>",
"       <p>",
"        (0.06-0.25)",
"       </p>",
"      </td>",
"      <td>",
"       0.12-0.25",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       0.015-0.125",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serratia marcescens",
"      </td>",
"      <td>",
"       <p>",
"        0.25",
"       </p>",
"       <p>",
"        (0.06-12.5)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        1",
"       </p>",
"       <p>",
"        (0.25-50)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        1",
"       </p>",
"       <p>",
"        (0.5-25)",
"       </p>",
"      </td>",
"      <td>",
"       0.12-12.5",
"      </td>",
"      <td>",
"       2-4",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stenotrophomonas maltophilia",
"      </td>",
"      <td>",
"       <p>",
"        2",
"       </p>",
"       <p>",
"        (2-25)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        4",
"       </p>",
"       <p>",
"        (4 - &gt;64)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        3.1",
"       </p>",
"       <p>",
"        (3 - &gt;25)",
"       </p>",
"      </td>",
"      <td>",
"       2-25",
"      </td>",
"      <td>",
"       1-4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MIC",
"     <sub>",
"      90",
"     </sub>",
"     : minimal inhibitory concentration for 90 percent of strains.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eliopoulos, GM, Eliopoulos, CT. Activity in vitro of the quinolones. In: Quinolone antimicrobial agents (2nd ed), Hooper, DC, Wolfson, JS (Eds), American Society for Microbiology, Washington, DC, 1993, p. 161, and Wolfson, JS, Hooper, DC, Clin Microbiol Rev 1989; 2:378. Perry, CM, Barman Balfour, JA, Lamb, HM. Drugs 1999; 58:683. Barman Balfour, JA, Wiseman, LR. Drugs 1999; 57:363. Blondeau, JM. J Antimicrob Chemother 1999; 43(SupplB):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33246=[""].join("\n");
var outline_f32_29_33246=null;
var title_f32_29_33247="DAH PA II";
var content_f32_29_33247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse alveolar hemorrhage due to inhalation of crack cocaine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a patient with diffuse alveolar hemorrhage due to inhalation of crack cocaine showing patchy upper zone opacities. The radiograph returned to normal in several days without specific treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_29_33247=[""].join("\n");
var outline_f32_29_33247=null;
